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Abstract
Approximately one third of the world’s population is infected with Mycobacterium
tuberculosis, the causative agent of tuberculosis. This bacterium has an unusual
lipid-rich cell wall containing a vast repertoire of antigens, providing a hydro-
phobic impermeable barrier against chemical drugs, thusrepresenting an attractive
target for vaccine and drug development. Apart from the mycolyl–arabinogalac-
tan–peptidoglycan complex, mycobacteria possess several immunomodulatory
constituents, notably lipomannan and lipoarabinomannan. The availability of
whole-genome sequences of M. tuberculosis and related bacilli over the past decade
has led to the identiﬁcation and functional characterization of various enzymes
and the potential drug targets involved in the biosynthesis of these glycoconju-
gates. Both lipomannan and lipoarabinomannan possess highly variable chemical
structures, which interact with different receptors of the immune system during
host–pathogen interactions, such as Toll-like receptors-2 and C-type lectins.
Recently, the availability of mutants defective in the synthesis of these glycoconju-
gates in mycobacteria and the closely related bacterium, Corynebacterium glutami-
cum, has paved the way for host–pathogen interaction studies, as well as, providing
attenuated strains of mycobacteria for the development of new vaccine candidates.
This review provides a comprehensive account of the structure, biosynthesis and
immunomodulatory properties of these important glycoconjugates.
Introduction
Tuberculosis (TB) is a major cause of death worldwide, with
approximately 9 million cases and 1.7 million deaths regis-
tered in 2008 (WHO, 2009). To compound this situation,
50000 cases were reported as multidrug-resistant tubercu-
losis (MDR-TB) and 55 countries globally had reported at
least one case of extensively drug-resistant tuberculosis
(XDR-TB) (WHO, 2009). Mycobacterium tuberculosis is the
causative agent of tuberculosis. It has an unusual lipid-rich
cell wall that is unique to the order Actinomycetes, including
the genera Mycobacterium, Rhodococcus, Corynebacterium
and Nocardia (Brennan & Nikaido, 1995). The mycobacter-
ial cell wall is composed of a mycolyl–arabinogalactan–pep-
tidoglycan (mAGP) complex (Daff´ e et al., 1990; McNeil
et al., 1990, 1991; Besra et al., 1995; Brennan, 2003; Dover
et al., 2004), of which the mycolic acids and extractable
lipids form the mycobacterial outer membrane (Hoffmann
et al., 2008). The mycolic acid layer provides a hydrophobic
mesh for intercalating additional complexlipids, resulting in
a highly impermeable barrier for the penetration of anti-
microbial drugs, such as penicillins (Amberson et al., 1931;
Minnikin et al., 2002). Other cell wall-associated lipids, such
as phosphatidyl-myo-inositol mannosides (PIMs) and lipo-
glycans, termed lipomannan (LM) and lipoarabinomannan
(LAM), are also found in the cell wall (Hill & Ballou, 1966;
Brennan & Ballou, 1967, 1968a; Brennan & Nikaido, 1995;
Besra et al., 1997; Morita et al., 2004). In addition to their
physiological function, these complex glycoconjugates play a
key role in modulating the host response during infec-
tion. PIMs, lipomannan and lipoarabinomannan all
display several immunomodulatory properties by interac-
tion with different receptors of the immune system.
While lipomannan is mainly associated with Toll-like
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Sreceptors (TLR) signaling, the higher-order PIMs and
mannose-capped lipoarabinomannan (Man-LAM) are re-
cognized by the C-type lectins, such as dendritic cell-speciﬁc
intercellular adhesion molecule-3 (ICAM-3) grabbing non-
integrin (DC-SIGN) and the macrophage mannose receptor
(MMR) (Schlesinger et al., 1994; Chatterjee & Khoo, 1998;
Nigou et al., 2002; Geijtenbeek et al., 2003; Maeda et al.,
2003).
Because of the advent of MDR and XDR strains of
M. tuberculosis (Sreevatsan et al., 1997; Telenti et al., 1997;
Heymann et al., 1998; Chan & Iseman, 2008; Wright et al.,
2009), there is an urgent need to identify novel drug targets
and the development of active compounds. In this respect,
the biosynthetic machinery of the mycobacterial cell wall,
which is the site of action of many front-line tuberculosis
drugs, represents an attractive drug target (Bhatt et al., 2007;
Bhowruth et al., 2007; Brennan & Crick, 2007; Dover et al.,
2008). Furthermore, a complete investigation of the roles of
PIMs, lipomannan and lipoarabinomannan in mycobacte-
rial pathogenicity requires mutants defective in their respec-
tive biosynthetic pathways. The availability of complete
genome sequences of several mycobacteria and related
actinomycetes and the development of novel tools for
genetic manipulation have opened up the possibilities to
achieve this (Cole et al., 1998).
Herein, we report recent advances in the biogenesis of
lipoarabinomannan and related glycoconjugates, followed
by a comprehensive analysis of their role in host–pathogen
interactions. Furthermore, we review the localization and
trafﬁcking of these immunomodulatory lipoglycans and
discuss recent ﬁndings concerning the role of CD1, TLR,
DC-SIGN and MMR in M. tuberculosis infection.
Part I -- Structure and biogenesis of PIMs,
lipomannan and lipoarabinomannan
Structural features of PIMs, lipomannan and
lipoarabinomannan
The majority of bacteria from suborder Corynebacterineae,
including Corynebacterium diphtheriae, Corynebacterium glu-
tamicum,p a t h o g e n i cM. tuberculosis complex and nonpatho-
genic Mycobacterium smegmatis, possess the amphipathic
lipoglycans, lipoarabinomannan and other related glycocon-
jugates, lipomannan and PIMs (Fig. 1). All Mycobacterium
species possess two forms of acylated PIMs, tri- and tetra-
acylated (Ac1-a n dA c 2-) phospho-myo-inositol-dimannoside
(PIM2) and tri- and tetra-acylated phospho-myo-inositol-
hexamannoside (Ac1/Ac2PIM6)( w eh a v eu s e dA c 1/Ac2PIMx
for two different acylated versions of PIMs throughout the
text, and PIM as a synonym where the acylation state is not
clear), and different acylated versions of lipomannan and
lipoarabinomannan (Khoo et al., 1995a), which are believed
to be noncovalently attached to the cell membrane via a lipid
anchor (Fig. 2) (Hunter & Brennan, 1990).
Structure of PIMs
PIMs are categorized as glycolipids composed of fatty acids
attached to a glycerol unit, linked by a phosphodiester
Fig. 1. Lipoarabinomannan and related glycoconjugates found on the cell wall of Mycobacterium tuberculosis, Mycobacterium smegmatis and
Corynebacterium glutamicum. Biochemical analysis of the mycobacterial cell wall suggests that different acylated variants of di- and hexa-mannosylated
PIMs, Ac1/Ac2PIM2 and PIM6, and the higher glycosylated polymers lipomannan and lipoarabinomannan accumulate in the cell wall. However, in C.
glutamicum, only PIM2, two types of lipomannan (LM-A and LM-B, Tatituri et al., 2007a; Mishra et al., 2008b) and singular Araf capped
lipoarabinomannan are present on the cell wall. For the purpose of simplicity, only diacylated forms of these glycoconjugates and LM-A, i.e. MPI
anchored lipomannan, are shown. In these glycoconjugates, phosphatidyl-myo-inositol (phosphate in gray and inositol in blue) acts as an anchor to the
plasma membrane and further glycosylated by Manp (green) and Araf (pink) sugars yielding different forms of PIMs, lipomannan and lipoarabino-
mannan that are species speciﬁc. In M. tuberculosis and other pathogenic mycobacteria, lipoarabinomannan is capped by mono, -di or -tri a(1 ! 2)-
Manp units, resulting in Man-LAM, while in nonpathogenic M. smegmatis, lipoarabinomannan is terminated by phospho inositol, yielding PI-LAM.
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1963) (see Fig. 2 for Ac2PIM2 and Ac2PIM6). This phospha-
tidyl-myo-inositol (PI) is based on an sn-glycero-3-phos-
pho-(1-D-myo-inositol) unit and is further substituted
at the O-2 and O-6 positions of myo-inositol with
a-D-mannopyranosyl (Manp) units in case of PIM2, result-
ing in a mannosyl phosphate inositol (MPI) anchor, a
derivative of the typical glycosyl phosphate inositol anchor,
found in Eukaryotes (Lee & Ballou, 1964; Chatterjee et al.,
1992a; Severn et al., 1998).
The MPI anchor is heterogeneous, with variations occur-
ring within the number, location and nature of the fatty
acids. There are four potential sites of acylation within the
MPI anchor, with different fatty acids at 1-OH and 2-OH of
the glycerol unit in the anchor, 3-OH of myo-inositol and
the 6-OH of the Manp residue linked at the O-2 position of
myo-inositol (see R1,R 2,R 3 and R4 in Fig. 2) (Khoo et al.,
1995a; Nigou et al., 2003). Two different acylated forms of
PIMs accumulate in the cell wall of mycobacteria, one with
an acyl group at either the 3-OH of myo-inositol or the 6-
OH of the Manp residue linked at the O-2 position of myo-
inositol, Ac1PIMx, and secondly with an acyl group at both
positions, Ac2PIMx. In mycobacteria, palmitic (C16) and
tuberculostearic (10-methyl-octadecanoic, C19) acids are
predominant, while myristic (C14) and octadecenoic acids
(C18:1) are also found in signiﬁcant amounts, with traces of
stearic (C18), hexadecenoic (C16:1) and heptadecanoic acids
(C17) (Ballou & Lee, 1964; Lee & Ballou, 1964;Gilleronet al.,
2003; Nigou et al., 2003). Furthermore, it was suggested that
the 6-OH position of the O-2 mannose attached to the
inositol of PIM2 is substituted by a C16 fatty acyl-substitu-
ent, which is also present in lipomannan and lipoarabino-
mannan from M. tuberculosis and Mycobacterium leprae
(Khoo et al., 1995a).
Acylated forms of PIM2 serve as substrates for the synthesis
of higher-order PIMs, such as Ac1/Ac2PIM6 (Figs 2 and 4).
Studies with a crude cell extract of M. tuberculosis and
Mycobacterium phlei identiﬁed PIM6, which is a pentamanno-
side attached to the position O-6 of the myo-inositol of PI of
PIM1,M a n p-a(1 ! 2)-Manp-a(1 ! 2)-Manp-a(1 ! 6)-
Manp-a(1 ! 6)-Manp-a(1 ! .)(Lee & Ballou, 1965), which
was later veriﬁed by others (Chatterjee et al., 1992a; Severn
et al.,1998)(Fig.2).AbiosyntheticrelationshipbetweenPIM1
and PIM2 was also suggested, which involves a stepwise
glycosylation of PI, ﬁrst at the O-2 position and then at the
O-6 position of the inositol ring (Ballou & Lee, 1964;
Chatterjee et al., 1992a). It was also suggested that this acylated
version of PIM2 i.e. Ac1PIM2 is both a metabolic end-product
Fig. 2. Schematic structures of lipoarabinomannan and related glycoconjugates. As described in the text, PI acts as an anchor around which PIMs,
lipomannan and lipoarabinomannan are built. PI is glycosylated at the 2-OH and 6-OH positions of inositol by Manp residues, and acylated at position 3
of myo-inositol and position 6 of the Manp unit linked at O-2 of myo-inositol in Ac2PIM2 (See the inset in light blue color). Manp at the 6-OH position of
inositol is linked to further threeand two residues of a(1 ! 6)-Manpand a(1 ! 2)-Manp,respectively,in Ac2PIM6(see the inset in lightindigocolor). In
lipomannan and the mannan backbone of lipoarabinomannan, PIM2 is linked to another 17–19 residues of Manp in the a(1 ! 6) direction and 7–9
singular branched a(1 ! 2)-Manp units. Mature lipomannan is further linked via an unknown linkage to an arabinan domain made up of
approximately 70 Araf residues. The majority of the arabinan domain consists of a linear a(1 ! 5)-Araf polymer branched at certain positions, with
a(3 ! 5)-Araf residues towards its nonreducing end resulting in a linear tetra-arabinoside or/and branched hexa-arabinoside domain, which in turn is
terminated by b(1 ! 2)-Araf and capped by a(1 ! 2)-Manp units. Here R1,R 2,R 3 and R4 show different acyl groups found at different locations in the
MPI anchor, and n, m, o, p and q represent different degrees of species-speciﬁc glycosylation in lipomannan and lipoarabinomannan.
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nomannan biosynthesis (Chatterjee et al., 1992a; Khoo et al.,
1995a; Besra et al., 1997).
More recently, the presence of a glucuronic acid diacyl-
glycerol-based glycolipid, Manp-a(1 ! 4)-D-glucopyrano
syluronic acid-diacyl glycerol, ManGlcAGroAc2, and a novel
lipomannan variant (Cg-LM-B) were reported in C. gluta-
micum, in addition to the MPI anchored-LM (Cg-LM-A)
and lipoarabinomannan, and to date, these glycoconjugate
variants have not been identiﬁed in mycobacteria (Tatituri
et al., 2007a; Lea-Smith et al., 2008; Mishra et al., 2008b,
2009). However, Rv0557 [MgtA] of M. tuberculosis was
shown to have the ability to synthesize these novel lipids
and lipoglycans in vitro and in vivo (Tatituri et al., 2007a;
Mishra et al., 2009), and the majority of the genus
Mycobacterium possesses an ortholog of MgtA. Therefore,
theoretically, the possibility remains for the identiﬁcation of
glucuronic acid-anchor-basedglycolipids in mycobacteria in
addition to MPI anchor-based ones.
Structure of lipomannan and lipoarabinomannan
In 1930, Masucci and colleagues isolated a polysaccharide
containing D-arabinofuranose (Araf) and Manp with high
serological activity from mycobacteria (Masucci et al.,
1930), which was also identiﬁed in Mycobacterium bovis
bacilli Calmette-Gu´ erin (BCG) (Chargaff & Schaefer, 1935),
and separated using electrophoresis (Seibert & Watson,
1941). Later, one of the polysaccharides was identiﬁed as
arabinogalactan (AG), the basic constituent of the mAGP
complex (Misaki & Yukawa, 1966), and the other as a pool
of immunologically active lipoarabinomannan and inactive
lipomannan (Misaki et al., 1977), both sharing a similar
mannan core (Hunter et al., 1986; Hunter & Brennan, 1990;
Chatterjee et al., 1992a) (Fig. 2). Further studies identiﬁed
Ac1/Ac2PIM2 as the attachment point (Hunter & Brennan,
1990) for the synthesis of the a(1 ! 6)-mannan backbone
of lipomannan and lipoarabinomannan, which is composed
of around 21–34 residues of a(1 ! 6)-Manp and decorated
by singular 5–10 units of a(1 ! 2)-Manp, resulting in the
formation of lipomannan (Chatterjee et al., 1992a; Kaur
et al., 2008). The mannan core is further elaborated by the
addition of an arabinan domain consisting of approximately
55–70 Araf residues in a linear a(1 ! 5)-D-Araf fashion
with 3,5-a-D-Araf branches (Kaur et al., 2008; Birch et al.,
2010). The arabinan domain is highly branched and con-
served with two types of chain arrangements. Firstly, linear
tetra-arabinoside (Ara-4) of the structure b-D-Araf(1 ! 2)-a-
D-Araf(1 ! 5)-a-D-Araf(1 ! 5)-a-D-Araf,a n ds e c o n d l y ,
branched hexa-arabinoside (Ara-6) motifs with the structure
[b-D-Araf(1 ! 2)-a-D-Araf]2-3,5-a-D-Araf(1 ! 5)-a-D-Araf
(Chatterjee et al., 1991; Chatterjee et al., 1993). In both cases,
the nonreducing end is characterized by the disaccharide unit,
Araf-b(1 ! 2)-Araf-a(1 ! .) (Fig. 2) (Chatterjee et al., 1991,
1993; McNeil et al., 1994).
The arabinan termini of lipoarabinomannan from the
Erdman strain of M. tuberculosis were shown to be capped
with Manp residues and it was established that the tetra-/
hexa-arabinofuranoside unit was further extended by mono,
di- and tri-a(1 ! 2)-D-Manp saccharide units (Fig. 2)
(Chatterjee et al., 1992b, 1993; Venisse et al., 1993). The
number of mannose caps is species speciﬁc, with M. tubercu-
losis H37Rv and M. bovis BCG Man-LAM equally capped
with around seven residues per molecule of lipoarabinoman-
nan (Khoo et al., 1995b; Nigou et al., 2003). Surprisingly,
lipoarabinomannan from a fast-growing Mycobacterium spe-
cies is devoid of any mannose cap (Chatterjee et al., 1992b)
and, in turn, a novel phosphoinositol capping motif was
identiﬁed from M. smegmatis strains ATCC 14468 and
mc
2155 (PI-LAM) (Fig. 1) (Khoo et al., 1995b) and the
Fig. 3. Biosynthetic pathways of important
nucleotide and lipid-linked sugar donors involved
in the synthesis of PIMs, lipomannan and
Man-LAM. Most of the sugars utilized by myco-
bacteria arederived from glycolytic intermediates
or glucose as the major carbon source. The
experimentally characterized enzymes have been
indicated in bold. Apart from the glycolytic
pathway, GDP-Manp,C 50-P-Manp,C 50-P-Araf
and PI are also derived from exogenous sources,
which have not been shown here to retain
simplicity.
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Mycobacterium chelonae, AraLAM (Gu´ erardel et al., 2002).
Further chemical modiﬁcations of
lipoarabinomannan
In its physiological form, Man-LAM is found in two
different fractions: parietal and cellular (Vercellone et al.,
1998; Gilleron et al., 2000; Hoffmann et al., 2008). These
fractions differ in terms of the percentage of mannose caps
and acylation groups of the MPI anchor. Parietal Man-LAM
possess a novel fatty acid assigned as 12-O-(methoxypropa-
noyl)-12-hydroxystearic acid, esteriﬁed at C-1 of the glycerol
residue of PI, while cellular Man-LAMs are largely hetero-
geneous with palmitic and tuberculostearic acid (Nigou
et al., 1997). More likely, cellular lipoarabinomannan is
more strongly attached to the cell wall due to higher
acylation as compared with parietal lipoarabinomannan
(Pitarque et al., 2008). Furthermore, in different M. bovis
BCG strains (Pasteur, Glaxo, Copenhagen and Japanese
strains), the presence of succinyl groups on O-2 of the 3,5-
di-a-D-Araf residue of Man-LAM was also reported (Delmas
et al., 1997). Recently, Treumann et al. (2002) identiﬁed a
5-methylthiopentose substituent on the terminal Manp in
the cap structure of Man-LAM in several strains of M.
tuberculosis, which was later characterized as 5-deoxy-5-
methylthio-xylofuranose (Turnbull et al., 2004) with a D-
conﬁguration (Joe et al., 2006) and linked by an a(1 ! 4)
linkage to a Manp residue in the mannan portion of the
glycan (Gu´ erardel et al., 2003).




Besides being part of glycolipids and lipoglycans, mannose is
also involved in the synthesis of a number of glycosylated
proteins (VanderVen et al., 2005) and a few other key
components, such as polymethylated polysaccharides in
mycobacteria (Jackson & Brennan, 2009). These molecules
are synthesized by both pathogenic and nonpathogenic
species, raising the possibility of as yet undeﬁned ‘house-
keeping’ functions in these organisms. The mannose
metabolism is essential for growth in M. smegmatis and it
was suggested that apart from glycolipid and lipoglycan
biosynthesis, mannose-containing molecules may also play a
role in regulating septation and cell division (Patterson et al.,
2003).
In mycobacteria, mannose is probably obtained by two
distinct pathways: ﬁrstly, by transport of extracellular man-
nose from the medium or the extracellular environment
with the activity of a hexokinase (Kowalska et al., 1980). The
phosphorylated mannose, mannose-1-phosphate, is then
converted into GDP-Manp by GDP-mannose pyropho-
sphorylase, ManC [Rv3264c] (Ning & Elbein, 1999; Ma
et al., 2001) (Fig. 3). Secondly, in the absence of extracellular
mannose, it can be derived from glucose and other sugars
via the glycolytic pathway, where fructose-6-phosphate is
converted to mannose-6-phosphate by an essential enzyme,
phosphomannose isomerase, encoded by manA [Rv3255c]
(Patterson et al., 2003). Mannose-6-phosphate is then con-
verted to mannose-1-phosphate by a phosphomannomu-
tase, ManB [Rv3257c] (McCarthy et al., 2005), followed by
conversion into GDP-Manp by ManC (Ning & Elbein, 1999;
Ma et al., 2001) (Fig. 3).
Synthesis of b-D-mannosyl-1-monophosphoryldecaprenol
GDP-Manp serves as an intracellular nucleotide-derived
mannose donor for the synthesis of several glycolipids and
mannosylated proteins by the GT-A/B superfamily of glyco-
syltransferases (Liu & Mushegian, 2003). However, for
periplasmic biosynthetic events, a polyprenyl-phosphate-
based mannose donor is required, which acts as a mannose
donor for the GT-C superfamily of glycosyltransferases
for the synthesis of higher PIMs, lipomannan and
Fig. 4. Overview of PIM biosynthesis in Mycobacterium tuberculosis. On the cytosolic side of the plasma membrane, PI is glycosylated by PimA, PimB’ and
an acyltransferase to form Ac1PIM2, which is further mannosylated by PimC and/or PimD? to form Ac1PIM4,a ni n t e r m e d i a t ei nA c 1PIM6 and lipomannan
biosynthesis. Ac1PIM4 is probably transported across the plasma membrane by unidentiﬁed ﬂippases and further mannosylated by a(1 ! 2)
mannopyranosyltransferases, PimE and/or another unidentiﬁed enzyme to form Ac1PIM6. For simplicity, only triacylated versions of PIMs are shown.
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ﬁrst to report the presence of a C50-polyprenol-based
mannolipid, C50-decaprenol-phospho-mannose (C50-P-
Manp, PPM), in M. tuberculosis (Takayama & Goldman,
1970). Later on, another alkali-stable, C35-octahydrohepta-
prenyl-phospho-mannose, C35-P-Manp, was identiﬁed in
M. smegmatis (Wolucka & Hoffmann, 1998). Based on
similarities to the known eukaryotic dolichol monopho-
sphomannose synthases, Rv2051c [Ppm1] from M. tubercu-
losis was identiﬁed as a polyprenol monophosphomannose
synthase, PPM synthase (Gurcha et al., 2002) (Figs 3 and 4).
Surprisingly, Ppm1 possesses an unusual two-domain archi-
tecture in M. tuberculosis, of which the second domain, Mt-
Ppm1/D2, is sufﬁcient for PPM synthesis (Gurcha et al.,
2002; Gibson et al., 2003). However, M. smegmatis, Myco-
bacterium avium and M. leprae produce two distinct pro-
teins, one for each of the two domains found in Mt-Ppm1,
with Ms-Ppm2 and Ma-Ppm2 having a catalytic activity
similar to that of domain 2 of Mt-Ppm1. Recently, a
transmembrane glycosyltransferase, Rv3779, was identiﬁed
and suggested to be involved in the synthesis of C35/50-P-
Manp as a second PPM synthase (Scherman et al., 2009).
However, Skovierova et al. (2010) recently described the
function of Rv3779 as the glycosyltransferase involved in
transferring galactosamine from a polyprenyl-phospho-N-
acetylgalactosamine to arabinogalactan in M. tuberculosis.
Origin and synthesis of decaprenyl-phospho-arabinose
Generally, in nature, D-arabinose exists in two cyclic forms: a
rare pyranose-ring (Arap) and the furanose-ring (Araf)
(Wolucka, 2008). Araf forms a key component of both
arabinogalactan and lipoarabinomannan in mycobacteria
and the only known Araf sugar donor is a lipid-linked
decaprenyl-phospho-arabinose (DPA and also termed C50-
P-Araf) (Wolucka et al., 1994). However, a putative role of a
nucleotide-based Araf donor was also suggested in the
addition of the single terminal D-Araf residues of lipoarabi-
nomannan in C. glutamicum (Tatituri et al., 2007b). The
majority of DPA synthesized in mycobacteria comes from
the pentose phosphate pathway (Marks, 1956). A transketo-
lase, Rv1449, links the glycolytic and pentose phosphate
pathway to produce ribose-5-phosphate (Wolucka, 2008).
Alternatively, ribose-5-phosphate isomerase [Rv2465] iso-
merizes D-ribulose-5-phosphate into ribose-5-phosphate
(Roos et al., 2004; Roos et al., 2005). Furthermore,
Rv1017c, a ribose-5-phosphate diphosphokinase (PrsA),
converts ribose 5-phosphate into 5-phosphoribosyl-a-1-
pyrophosphate (pRpp) (Alderwick et al., 2010), which is
dephosphorylated by a phosphatase as the ﬁrst committed
step in decapolyprenol-phosphoribose (DPR and also
termed C50-P-Rib) and DPA biosynthesis (Mikusov´ a et al.,
2005) (Fig. 3). In the genome of M. tuberculosis,a n
unknown poly-(A)-polymerase2 (PAP2)-superfamily phos-
pholipid phosphatase [Rv3807c] exists that is present in the
arabinogalactan biosynthetic cluster (Rv3779-Rv3809c) and
next to Rv3806c, UbiA (Huang et al., 2005), which may be
responsible for pRpp phosphatase activity. Furthermore, the
deletion of the Rv3807c homolog in C. glutamicum remains
unsuccessful, suggesting it as a prime candidate (L. Eggeling
& G.S. Besra, unpublished data).
The synthesis of DPA and DPR from pRpp was shown
experimentally and it was concluded that DPA is formed
from pRpp via a two-step pathway, with an additional
epimerization step that converts DPR to DPA (Scherman
et al., 1996; Mikusov´ a et al., 2005) (Fig. 3). Recently,
a5 - p h o s p h o - a-D-ribose-1-diphosphate:decaprenyl-phosphate
5-phospho-ribosyltransferase, UbiA [Rv3806c], was identi-
ﬁed in M. tuberculosis (Huang et al., 2005). The deletion of
ubiA in C. glutamicum produced a mutant that possessed a
galactan core consisting of alternating b(1 ! 5)-galactofur
anose (Galf) and b(1 ! 6)-Galf residues and completely
devoid of arabinan and cell-wall-bound corynomycolic
acids, conﬁrming its role in the synthesis of DPR and DPA
biosynthesis in Corynebacterineae (Alderwick et al., 2005;
Alderwick et al., 2006a). More recently, Mikusov´ a et al. (2005)
identiﬁed an epimerase, which is involved in the epimeriza-
tion of DPR to DPA. It was established that the 2-OH
of ribose is oxidized to decaprenylphosphoryl-2-keto-b-
D-erythro-pentofuranose, which is then reduced to form
DPA. These activities are encoded by Rv3790 and Rv3791,
respectively, and the simultaneous expression of both is
required for complete activity of the epimerase reaction
(Mikusov´ a et al., 2005) (Fig. 3). Interestingly, Rv3790 has been
shown to be a target of benzothiazinones, potential tubercu-
losis drugs (Christophe et al., 2009; Makarov et al., 2009).
Synthesis of phosphatidyl-myo-inositol
Inositol is an essential metabolite in Mycobacterium (Katao-
ka & Nojima, 1967), Corynebacterium (Brennan & Lehane,
1971), Nocardia (Yano et al., 1969), Micromonospora (Ta-
baud et al., 1971) and Propionibacterium (Brennan & Ballou,
1968b). In mycobacteria, inositol is essential for growth and
derived directly via glycolysis (Jackson et al., 2000). Glucose-
6-phosphate is cyclized by an inositol-1-phosphate synthase,
Ino1 [Rv0046c] (Bachhawat & Mande, 1999; Movahedzadeh
et al., 2004), into myo-inositol-1-phosphate, followed by its
dephosphorylation utilizing an inositol monophosphatase
(IMP) (Fig. 3). On the basis of homology, the M. tuberculosis
genome shows four ORFs encoding putative proteins with
an IMP domain: Rv1604 (ImpA), Rv2701c (SuhB), Rv2131c
(CysQ) and Rv3137 (ImpC). Out of these, impC was found
to be essential for mycobacterial growth, and it was sug-
gested that impA, suhB and cysQ may make a minor
contribution towards inositol biosynthesis (Movahedzadeh
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(Fig. 3) (Parish et al., 1997; Nigou & Besra, 2002a; Brown
et al., 2007).
The ﬁrst step in the production of many phospholipids,
including PI, is the phosphorylation of diacylglycerol(DAG)
by a diacylglycerol kinase [Rv2252] to form phosphatidic
acid (Owens et al., 2006). Phosphatidic acid is then activated
by CTP to form CDP-DAG by a CDP-DAG synthase
[Rv2881c], a homolog of which has been characterized in
M. smegmatis (Nigou & Besra, 2002b). Furthermore, it was
shown that a cell wall fraction (Percoll-60, P60) from M.
smegmatis is able to synthesize P-[
3H]-I in the presence of
the exogenous substrate, CDP-dipalmitoyl-DAG, conclud-
ing that myo-inositol reacts with CDP-DAG and forms PI
(Salman et al., 1999). Recently, the gene encoding the PgsA
[Rv2612c] has been identiﬁed and shown to be essential in
M. tuberculosis (Jackson et al., 2000) (Fig. 3).
Overview of PIM biosynthesis
The current model of mycobacterial PIM biosynthesis
supported by biochemical and genetic studies follows a
linear pathway from PI ! PIM2 ! PIM4 ! PIM6 (Fig. 4)
(Chatterjee et al., 1992a; Besra & Brennan, 1997; Morita
et al., 2004, 2006). Glycosylation of PI by different a-
mannopyranosyltransferases, PimA, PimB’, PimC, unidenti-
ﬁed PimD?, PimE, unidentiﬁed PimF? and acylation by
acyltransferase(s), results in the synthesis of Ac1/Ac2PIMs
(Kordulakova et al., 2002, 2003; Kremer et al., 2002; Morita
et al., 2006; Lea-Smith et al., 2008; Guerin et al., 2009;
Mishra et al., 2009), out of which Ac1/Ac2PIM2 and
Ac1/Ac2PIM6 accumulate onto the mycobacterial cell wall
(Figs 1 and 4).
Conversion of PI into Ac1PIM1
The enzymes involved in the synthesis of early PIMs are
encoded by a conserved cluster of six ORFs in an operon,
which is found in all members of Corynebacterineae (Cole &
Barrell, 1998; Cole et al., 1998). The ﬁrst ORF of this cluster,
Rv2614c, encodes a protein with an aminoacyl-tRNA
synthase class-II motif and is similar to Escherichia coli
threonyl-t-RNA synthases. The second ORF, Rv2613c, has
similarity to the proteins involved in nucleotide biosynth-
esis, while the third ORF, Rv2612c, encodes for PgsA and the
fourth ORF, Rv2611c, encodes an acyltransferase. An
M. smegmatis Rv2611c mutant exhibited severe growth
defects and accumulated nonacylated PIM1 and PIM2,
suggesting its role in acylation of PIMs. Further biochemical
analysis suggested that Rv2611c acylates the 6-position of
Manp residue linked to the 2-OH position of myo-inositol
(Kordulakova et al., 2003). Very recently, the identiﬁcation
of an a-D-mannose-a(1 ! 6)-phosphatidyl-myo-inositol-
mannopyranosyltransferase, PimB’, involved in the biosynth-
esis of Ac1/Ac2PIM2, shed further light on the acylation step
in PIM biosynthesis. The deletion of pimB’i nC. glutamicum
resulted in the abrogation of Ac1/Ac2PIM2 and the accumula-
tionofAc1PIM1 (Lea-Smithetal.,2008; Mishraetal.,2008b),
suggesting that the ﬁrst acylation step, i.e. acylation of PIM1
(Kordulakova et al., 2003), precedes the second mannosyla-
tion step, resulting in the formation of Ac1PIM2 (Schaeffer
et al., 1999).
PimA [Rv2610c] is the ﬁfth ORF of the operon and is
essential in M. smegmatis (Kordulakova et al., 2002). In cell-
free assays with partially puriﬁed Rv2610c and/or mem-
branes from M. smegmatis overexpressing PimA and GDP-
[
14C]-Manp, Kordulakova et al. (2002) identiﬁed the incor-
poration of radioactivity into PIM1 and Ac1PIM1. They
deduced that Rv2610c encodes for an a-mannopyranosyl-
transferase and that PimA is responsible for the formation of
PIM1 from PI and GDP-Manp (Kordulakova et al., 2002).
The crystal structure of PimA in complex with GDP-Manp
from M. smegmatis shows a two-domain organization with
the catalytic machinery typical of GT-B glycosyltransferases
(Guerin et al., 2007). The sixth ORF, Rv2609c, encodes for a
putative GDP-Manp hydrolase containing a mutT domain
(see below for further discussion).
Synthesis of Ac1PIM2, an important step in higher PIMs,
lipomannan and lipoarabinomannan biosynthesis
Recently, Rv2188c and its homologs in C. glutamicum (Lea-
Smith et al., 2008; Mishra et al., 2008b) and M. smegmatis
(Guerin et al., 2009) were identiﬁed as PimB’. This identiﬁ-
cation augmented the confusion in the ﬁeld, as another
gene, Rv0557, had already been assigned the function of
PimB as an a-D-mannose-a(1 ! 6)-phosphatidyl-myo-in
ositol-mannopyranosyltransferase (Schaeffer et al., 1999).
This study was based on the utilization of cell-free assays
using GDP-[
14C]-Manp,A c 1PIM1, M. smegmatis mem-
branes and/or partially puriﬁed recombinant Rv0557
(Schaeffer et al., 1999). Furthermore, the disruption of
Rv0557 in M. tuberculosis did not affect the biosynthesis of
Ac1PIM2 (Torrelles et al., 2009), suggesting either gene
duplication or that Rv0557 performed another function in
M. tuberculosis. Recently, Rv0557 was shown to be involved
in the biosynthesis of ManGlcAGroAc2 and a Cg-LM-B (also
see Structure of PIMs) in C. glutamicum, and has been
suggested to have an a-mannosyl-glucopyranosyluronic
acid transferase, MgtA, activity (Tatituri et al., 2007a).
To solve this puzzle, involving PimB, PimB’ and MgtA,
and to assign the correct function to each ORF, a double
mutant deﬁcient in orthologs of Rv0557 and Rv2188c was
generated in C. glutamicum, and subsequently, Rv0557 and
Rv2188c were overexpressed in the double mutant. Conse-
quently, the in vivo complementation of a-D-mannose-
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ase activity was restored using plasmid-borne copies of
Rv2188c resulting in the synthesis of Ac1PIM2 and the
related lipoglycan in the C. glutamicum double mutant,
while overexpression of Rv0557 resulted in the synthesis of
ManGlcAGroAc2, suggesting that Rv0557 has an a-manno-
syl-glucopyranosyluronic acid transferase activity, and
therefore, Rv2188c was suggested to be Mt-PimB, while
Rv0557 was renamed as Mt-MgtA (Mishra et al., 2009). For
consistency with the recent literature, we retain the designa-
tion PimB’ for Rv2188c (and its orthologs in M. smegmatis
and C. glutamicum) (Lea-Smith et al., 2008; Mishra et al.,
2008b, 2009; Guerin et al., 2009). The crystal structure of
C. glutamicum PimB’ in complex with GDP vs. GDP-Manp
shows the selectivity of PimB’ for 6-OH of the inositol
moiety of PI (Batt et al., 2010). Rv0557 possesses relaxed
substrate speciﬁcity towards Ac1PIM1 (Schaeffer et al., 1999;
Mishra et al., 2009) and its deletion from M. tuberculosis
resulted in a viable mutant with a subtle decrease in
the lipomannan and lipoarabinomannan contents (Torrelles
et al., 2009), indicating a superﬁcial role of Rv0557
in the biosynthesis of PIMs, lipomannan and lipo-
arabinomannan. In contrast, Rv2188c is essential in
M. smegmatis (Guerin et al., 2009), illustrating an example
of a high-duplication event that lead to extensive func-
tional redundancy in mycobacteria (Cole et al., 1998; Tekaia
et al., 1999).
More recently, the role of glycosyl hydrolases has been
suggested in the regulation of glycolipid ﬂux inside and
outside the cell membrane and it was suggested that these
glycosyl hydrolases work in close coordination with glyco-
syltransferases (Crespo et al., 2010). The presence of GDP-
Manp hydrolases in the vicinity of pimA and pimB’, suggests
the metabolic role of these glycosyl hydrolases in the
regulation of the sugar donors and glycolipids, such as
GDP-Manp, PPM and PIMs. In addition, the presence of
putative transporters Rv2190c in M. tuberculosis and
NCgl2107 and NCgl2108 in C. glutamicum in the vicinity of
pimB’ region suggests their role in PIM or PPM transport in
Corynebacterineae. However, the deletion of the homolog of
Rv2190c in C. glutamicum resulted in a viable mutant with
no phenotype, suggesting gene redundancy, which is not
surprising as these putative transporters are present in
multicopies elsewhere in the genome (L. Eggeling & G.S.
Besra, unpublished data). Futurestudies targeting the roleof
these glycosyl hydrolases and transporters may shed further
light on the regulation of PIMs, lipomannan and lipoarabi-
nomannan in mycobacteria.
Synthesis of higher-order PIMs
Bioinformatical analysis of the genome of M. tuberculosis
CDC1551 has led to the identiﬁcation of RvD2-ORF1 from
M. tuberculosis CDC1551 as an Ac1PIM2:a-D-mannose-
a(1 ! 6)-phosphatidyl-myo-inositol-mannopyranosyltransfer-
ase, PimC, involved in the addition of Manp from GDP-
Manp to the 6-OH of mannose at the nonreducing end of
Ac1/Ac2PIM2 (Kremer et al., 2002). The use of a cell-free
assay containing GDP-Manp, amphomycin (an antibiotic
that inhibits the synthesis of PPMs by inhibiting the PPM
synthase) and membranes from M. smegmatis-overexpres-
sing PimC led to the synthesis of Ac1/Ac2PIM3. However, the
inactivation of pimC in M. bovis BCG did not affect the
production of higher PIMs, lipomannan and lipoarabino-
mannan, and the fact that genes orthologous to pimC were
found in only 22% of clinical isolates suggests the existence
of redundant gene(s) or an alternate pathway that may
compensate for PimC deﬁciency (Kremer et al., 2002).
Ac1/Ac2PIM3 is further a(1 ! 6) mannosylated at the
nonreducing termini by an unidentiﬁed a(1 ! 6)-manno-
pyranosyltransferase [PimD] or PimC itself, resulting in the
formation of Ac1/Ac2PIM4. This step in the biosynthesis of
higher PIMs,lipomannan and lipoarabinomannan, hasbeen
suggested as a keybranch point towardsthe synthesis of Ac1/
Ac2PIM6, lipomannan and lipoarabinomannan (Morita
et al., 2004; Morita et al., 2006; Mishra et al., 2008a). It has
been proposed that a transition occurs from glycosyltrans-
ferases, utilizing nucleotide-derived sugar substrates,
characterized by the GT-A/B superfamily, to the glycosyl-
transferases utilizing polyprenyl-phosphate sugars, the GT-
C superfamily (Liu & Mushegian, 2003), for the elongation
and branching of lipomannan and lipoarabinomannan
(Morita et al., 2006). Rv1159 [PimE] has been identiﬁed as
an a(1 ! 2)-mannopyranosyltransferase that utilizes PPM
as a substrate and adds an a(1 ! 2)-Manp to Ac1/Ac2PIM4,
resulting in the synthesis of Ac1/Ac2PIM5 (Fig. 4) (Morita
et al., 2006). However, it is not clear whether PimE is solely
responsible for the synthesis of both Ac1/Ac2PIM5 and Ac1/
Ac2PIM6. So far, most of the putative glycosyltransferases
belonging to the GT-C family (Liu & Mushegian, 2003) in
M. tuberculosis have been functionally characterized. That
leaves us with fewer possibilities, in which either PimE
or one of the other uncharacterized GT-Cs (Rv0051 and
Rv0541c) (Liu & Mushegian, 2003; Berg et al., 2007) adds
the second Manp residue onto Ac1/Ac2PIM5. However, an
Rv0051 deletion mutant showed no phenotypic change in
the cell wall glycolipid of M. tuberculosis (A.K. Mishra &
G.S. Besra, unpublished data), leaving Rv0541c as a promis-
ing candidate.
Morita et al. (2005) suggested that enzymes involved
in the biosynthesis of early PIM intermediates (PIM1 and
Ac1PIM1) are localized to a membrane subdomain termed
PMf in the plasma membrane, while the majority of Ac1/
Ac2PIM2 (and biosynthetic enzymes) involved in higher-
order PIM (Ac1/Ac2PIM4 and Ac1/Ac2PIM6) biosynthesis
are localized to a denser fraction that contains both plasma
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2005). On the basis of various cell-free assays, they con-
cluded that higher PIM biosynthesis occurs in the plasma
membrane rather than the PM-CW fraction, followed by
their subsequent transport to the cell wall (Morita et al.,
2005). The relative amount of higher PIMs and lipoglycans
was suggested to be regulated by a recently identiﬁed
lipoprotein [LpqW] in M. smegmatis (Kovacevic et al.,
2006; Marland et al., 2006). However, the exact mechanism
of PIM ﬂux and its segregation for Ac1/Ac2PIM6 or lipo-
mannan biosynthesis is unknown. Furthermore, Ac1/Ac2-
PIM4 was suggested to be a key regulatory product involved
in the biosynthesis of Ac1/Ac2PIM6 and/or lipomannan
biosynthesis (Morita et al., 2004, 2006). PimE directs Ac1/
Ac2PIM4 towards Ac1/Ac2PIM6 synthesis, while LpqW chan-
nels Ac1/Ac2PIM4 for lipomannan synthesis (Crellin et al.,
2008). It is speculated that Ac1/Ac2PIM4 is transported by a
ﬂippase or a sugar transporter across the plasma membrane,
where subsequent mannosylation occurs by distinct man-
nopyranosyltransferases belonging to the GT-C family (Liu
& Mushegian, 2003; Mishra et al., 2008a).
Recently, the role of a putative acyl transferase, Rv1565c,
was suggested in the acylation of higher-order PIMs, lipo-
mannan and lipoarabinomannan. An Rv1565c deletion
mutant in Mycobacterium marinum showed a reduced
incorporation of 1,2-[
14C]-acetate into the PIMs, lipoman-
nan and lipoarabinomannan as compared with the wild
type. Furthermore, lipoarabinomannan from the mutant
lacks mannose caps and showed a higher degree of branch-
ing of both the arabinan domain and the mannan core,
suggesting some important and unidentiﬁed role of
Rv1565c in mycobacteria (Driessen et al., 2010).
Overview of lipomannan and lipoarabinomannan
biosynthesis
Synthesis of the mannan core
Using mutant constructs in C. glutamicum, and cell-free
assays, two a(1 ! 6)-mannopyranosyltransferase activities
were reported from C. glutamicum, of which one enzyme
(M. tuberculosis homolog, Rv2174) was characterized as
MptA and shown to be involved in the synthesis of the distal
end of the a(1 ! 6) mannan backbone of lipomannan
(Kaur et al., 2007; Mishra et al., 2007), while a second
a(1 ! 6)-mannopyranosyltransferase, Rv1459c (MptB),
was shown to be involved in the synthesis of the proximal
end of the mannan backbone and speculated to extend an
Ac1/Ac2PIM4 acceptor (Fig. 5) (Mishra et al., 2008a). The
deletion of the MptB ortholog in C. glutamicum resulted in
the absence of lipomannan and lipoarabinomannan and a
reduction in a(1 ! 6)-mannopyranosyltransferase activity.
Furthermore, cell-free assays involving C50-P-Manp and
heterologously expressed Rv1459c and/or its M. smegmatis
homolog MSMEG_3120in C. glutamicum showedthatthese
enzymes possessed a(1 ! 6)-mannopyranosyltransferase
Fig. 5. Biogenesis of Man-LAM from Mycobacterium tuberculosis.A c 1/Ac2PIM4 plausibly serves as an acceptor and extended by MptB in the a(1 ! 6)
direction, followed by MptA and further decorated by singular a(1 ! 2)-Manp units by Rv2181 (MptC), resulting in lipomannan. Mature lipomannan is
subsequently primed by a singular D-Araf at an unknown position, which is extended by EmbC and/or unidentiﬁed a(1 ! 5) arabinofuranosyltrans-
ferases. The linear a(1 ! 5)-D-Araf chain is further primed by AftC, which is subsequently extended by AftD and unknown arabinofuranosyltrans-
ferases and terminated by the action of AftB to form linear Ara-4 or branched Ara-6. The penultimate Araf of the arabinan domain is further capped by
Manp residues by CapA and Rv2181 (MptC) to form Man-LAM. For simplicity, only triacylated versions of different lipoglycans are shown.
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transport of Ac1PIM4 outside the plasma membrane by an
unidentiﬁed ﬂippase, Mt-MptB catalyzes the addition of
further 12–15 Manp units (Mishra et al., 2008a). MptB is
part of an operon that consists of four ORFs encoding ATP-
binding cassette (ABC) transporters (Wang et al., 2006).
This enhances a strong possibility for a functional coupling
of the glycosyltransferase MptB with ABC transporters,
Rv1458c, Rv1457c and Rv1456c. However, a C. glutamicum
mutant deﬁcient in these ABC transporters showed no
difference in their PIM, lipomannan and lipoarabinoman-
nan proﬁles (L. Eggeling & G.S. Besra, unpublished data),
suggestive of gene redundancy, which is not surprising as
these ABC transporters are found at multiple locations in
the genome of Corynebacterineae.
Interestingly, a(1 ! 6) mannan extension is more com-
plex in mycobacteria, based on the evidence that Mt-MptB
and Ms-MptB fail to complement the C. glutamicumnmptB
mutant, suggesting a slightly different substrate speciﬁcity of
the MptB orthologs of M. tuberculosis and M. smegmatis as
compared with Cg-MptB (Mishra et al., 2008a). Further-
more, the redundancy of Ms-MptB in M. smegmatisnmptB
indicates that either another as yet unidentiﬁed mannopyr-
anosyltransferase is substituting for MptB in the mutant or
the distal a(1 ! 6)-mannopyranosyltransferase, MptA, is
substituting for the deﬁciency of Ms-MptB. A mycobacterial
strain devoid of MptA and MptB may shed further light on
this aspect.
In order to identify the a(1 ! 6)-mannopyranosyltrans-
ferase involved in the synthesis of the distal a(1 ! 6)
mannan backbone, the homologs of putative glycosyltrans-
ferase, Rv2174, were deleted from C. glutamicum (Mishra
et al., 2007) and M. smegmatis (Kaur et al., 2007). The cell
wall phenotype of the mutants suggested the accumulation
of a truncated lipoglycan (t-LM), deﬁcient in a(1 ! 6)-
Manp units. A cell-free assay involving C50-P-Manp and a
synthetic disaccharide acceptor, Man-a(1 ! 6)-Man-C8,
established that the mutant lacked a(1 ! 6)-mannopyra-
nosyltransferase activity and was termed MptA (Mishra
et al., 2007). Pfam analysis (Bateman et al., 2004) of the
ORF upstream of mptA revealed that Rv2173 (putative
geranylgeranyl pyrophosphate synthetase, idsA2) bears
structural similarities to polyprenyl synthetases, whichcould
be functionally related to MptA, and both genes may form a
transcriptional unit. Interestingly, mycobacterial MptA con-
tains 13 transmembrane helixes (TMH), of which TMH 3
and 4 are conserved and contain the catalytic DXD motif
typiﬁed by glycosyltransferases (Liu & Mushegian, 2003),
while the C-terminus extracellular loop is nonexistent, un-
like other GT-C glycosyltransferases (Zhang et al., 2003;
Alderwick et al., 2011), suggesting the existence of a
different model for chain extension as reported already in
the case of M. tuberculosis EmbC (Shi et al., 2006). Further-
more, the recent genome analysis of Actinobacterium and
Micrococcus luteus identiﬁed the presence of homologs of
MptA and MptB in a cluster with another gene encoding for
a GT-C glycosyltransferase, which are cotranscribed and
probably translationally coupled (Young et al., 2010). In
contrast, MptA and MptB are dispersed in corynebacteria
and mycobacteria.
The a(1 ! 6) mannan core in lipomannan and lipoar-
abinomannan is further decorated by single a(1 ! 2)-
Manp branches (Hunter & Brennan, 1990; Chatterjee et al.,
1992a). On the basis of known polyprenol-dependent gly-
cosyltransferases, Rv2181 (MptC), was identiﬁed from an
18-kb conserved region and suggested to be involved in the
synthesis of a(1 ! 2)-Manp side chains of lipomannan
(Fig. 5) (Kaur et al., 2006; Kaur et al., 2008; Sena et al.,
2010; Mishra et al., 2011). More recently, it was suggested
that MptA and MptC may act in close coordination to
synthesize mature lipomannan and lipoarabinomannan,
and the length of the mannan core may be regulated by a
branching-dependent chain termination mechanism (Sena
et al., 2010).
Arabinan domain assembly of lipoarabinomannan
Ac1/Ac2-PIM2 is extended by MptB, MptA and MptC to
yield a mature lipomannan that probably serves as an
acceptor for an uncharacterized arabinofuranosyltransferase
to initiate lipoarabinomannan synthesis (Besra et al., 1997).
However, the number of arabinofuranosyltransferases re-
quired for arabinan domain biosynthesis will depend on the
types of arabinan linkage present in mycobacterial lipoar-
abinomannan (Fig. 5). It is quite likely that mature lipo-
mannan is primed by a few Araf units in a similar fashion as
AftA primes the galactan of arabinogalactan in mycobacteria
(Alderwick et al., 2006c). However, the enzyme responsible
for this activity is not known. The primed Araf-LM is then
further extended by EmbC (Rv3793) (Zhang et al., 2003; Shi
et al., 2006; Alderwick et al., 2011) for 12–16 a(1 ! 5)-Araf
residues (Birch et al., 2010). Recently, AftC (Rv2673) was
shown to introduce the a(1 ! 3)-Araf branch points in
both arabinogalactan (Birch et al., 2008) and lipoarabino-
mannan (Birch et al., 2010). This a(1 ! 3)-Araf branched
product, [Araf]12–16-LM, is then further extended by an
unidentiﬁed a(1 ! 5)-arabinofuranosyltransferase.
More recently, Skovierova et al. (2009) proposed a second
branching a(1 ! 3)-arabinofuranosyltransferase, AftD
(Rv0236c). However, unlike the role of AftC as an
a(1 ! 3)-arabinofuranosyltransferase, which was experi-
mentally validated by creating a knockout in M. smegmatis
defective in a(1 ! 3)-arabinofuranosyltransferase activity
(Birch et al., 2008), the role of AftD is debatable as
Skovierova et al. (2009) were unable to create a viable
mutant displaying a clear phenotype, and the study was
FEMS Microbiol Rev 35 (2011) 1126–1157 c   2011 Federation of European Microbiological Societies
Published by Blackwell Publishing Ltd. All rights reserved
1135 Structure, function and biogenesis of lipoarabinomannansolely based on the usage of artiﬁcial chemically deﬁned
acceptors using crude M. smegmatis and C. glutamicum
membranes (Skovierova et al., 2009). It is also interesting
to note that the same authors also discussed the possibility
of AftD as an a(1 ! 5)-arabinofuranosyltransferase in-
volved in a(1 ! 5)-Araf extension of the nonreducing
termini of the arabinan domain of lipoarabinomannan and
arabinogalactan (Skovierova et al., 2009) (Fig. 5).
The ﬁnal enzyme involved in arabinan domain biosynth-
esis is AftB (Rv3805c), which results in a terminal tetra- and
hexa-arabinofuranoside structure (Figs 2 and 5). The role of
AftB has been experimentally shown to be a b(1 ! 2)-
arabinofuranosyltransferase in the synthesis of arabinoga-
lactan (Seidel et al., 2007). However, its role in the synthesis
of similar Araf residues in lipoarabinomannan is highly
likely after the discovery of a dual role of AftC in arabino-
galactan (Birch et al., 2008) and lipoarabinomannan (Birch
et al., 2010) biosynthesis.
Mannan priming and Man-LAM synthesis
All pathogenic species of the genus Mycobacterium are
known to possess Man-LAM, which is responsible for some
of the immunomodulatory properties of these strains (Bri-
ken et al., 2004). A close inspection of the M. tuberculosis
genome in comparison with M. smegmatis that possesses
lipoarabinomannan without mannose caps provided the
ﬁrst indication of the role of Rv1635c in Man-LAM bio-
synthesis. On this basis, the homolog of Rv1635c in
M. tuberculosis CDC1551 was identiﬁed as a glycosyltrans-
ferase that could be involved in Man-LAM capping (Dina-
dayala et al., 2006). Simultaneously, mutants of Rv1635c
homologs in M. marinum and M. bovis BCG showed that
the gene encoded for an a(1 ! 5)-mannopyranosyltrans-
ferase, CapA, was involved in the addition of the ﬁrst Manp
residue on the nonreducing arabinan termini of lipoarabi-
nomannan (Appelmelk et al., 2008). More recently, it was
also shown that MptC (Rv2181), which adds a(1 ! 2)-
Manp residues onto the a(1 ! 6) mannan backbone of
lipomannan and lipoarabinomannan, also adds a(1 ! 2)-
Manp caps at the nonreducing end of lipoarabinomannan in
combination with CapA (Kaur et al., 2008) (Fig. 5). Our
recent studies with an M. bovis BCG mutant defective in
pimE also suggested its tentative role in a(1 ! 2)-Manp
capping of Man-LAM (G.S. Besra & B.J. Appelmelk, unpub-
lished data). However, more studies are needed to establish
the exact interplay of these mannopyranosyltransferases
involved in the mannan caps of Man-LAM.
Almost the entire repertoire of enzymes and genes
involved in the biogenesis of lipoarabinomannan and re-
lated glycoconjugates has been identiﬁed (Table 1),
and some of these genes are essential for the survival of
Table 1. Experimentally characterized genes involved in the biosynthesis of LAM and related glycoconjugates
ORF Function Role References
PgsA (Rv2612c) PI synthase Synthesis of Phosphatidyl-myo-
inositol
Jackson et al. (2000)
PimA (Rv2610c) a(1 ! 2)-Mannopyranosyltransferase Synthesis of PIM1 Kordulakova et al. (2002)
Rv2611c Acyltransferase Synthesis of Ac1/Ac2-PIM1 Kordulakova et al. (2003)
PimB’ (Rv2188c) a(1 ! 6)-Mannopyranosyltransferase Synthesis of Ac1/Ac2-PIM2 Lea-Smith et al. (2008); Mishra et al.
(2008b, 2009)
MgtA/PimB (Rv0557) a(1 ! 6)-Mannopyranosyltransferase Synthesis of ManGlcGroAc2 and
Ac1/Ac2-PIM2
Tatituri et al. (2007a,b); Mishra et al.
(2008b)
PimC (RvD2-ORF1) a(1 ! 6)-Mannopyranosyltransferase Synthesis of Ac1/Ac2-PIM3 Kremer et al. (2002)
PimE (Rv1159) a(1 ! 2)-Mannopyranosyltransferase Synthesis of Ac1/Ac2-PIM5 Morita et al. (2006)
MptB (Rv1459c) a(1 ! 6)-Mannopyranosyltransferase Synthesis of proximal mannan
backbone i.e. Ac1/Ac2-PIM12–17
Mishra et al. (2008a)
MptA (Rv2174) a(1 ! 6)-Mannopyranosyltransferase Synthesis of distal mannan backbone
i.e. Ac1/Ac2-PIM22–25
Mishra et al. (2007)
MptC (Rv2181) a(1 ! 2)-Mannopyranosyltransferase Adds a(1 ! 2)-Manp units on the
mannan backbone, and also adds a
second mannose cap on ManLAM
Kaur et al. (2008, 2010); Mishra et al.
(2011)
EmbC (Rv3793) a(1 ! 5)-Arabinofuranosyltransferase Involved in the synthesis of the
a(1 ! 5)-arabinan backbone
Zhang et al. (2003); Alderwick et al.
(2011)
AftC (Rv2673) a(1 ! 3)-Arabinofuranosyltransferase Adds Araf on a(1 ! 5)-arabinan
backbone in the a(3 ! 5)-direction
Birch et al. (2010)
AftD (Rv0236c) a(1 ! 3) or a(1 ! 5)-
Arabinofuranosyltransferase
Either adds a(1 ! 3)-Araf units to the
non-reducing end of the a(1 ! 5)-
arabinan branch or synthesize
a(1 ! 5) itself
Skovierova et al. (2009)
CapA (Rv1635c) a(1 ! 5)-Mannopyranosyltransferase Adds ﬁrst mannose cap on ManLAM Appelmelk et al. (2008)
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However, the roles of lipoarabinomannan and related gly-
coconjugates in mycobacterial pathogenicity require the
availability of mycobacterial mutants defective in their
respective biosynthetic pathways, as most of the studies have
been carried out using puriﬁed molecules that do not
represent the true in vivo condition during infection. The
availability of complete genome sequences of several myco-
bacteria and related actinomycetes and the development of
novel tools for genetic manipulation have enhanced these
possibilities.
Part II -- Interactions with host
immune system
Accessibility of lipoglycans to the immune
system: localization and trafficking
Lipoarabinomannan and related lipoglycans are not only
essential for mycobacterial growth and cell viability (Haites
etal., 2005;Kovacevic etal., 2006), but arealso thoughtto be
important in the interactions between the mycobacteria and
their host. The nature of these host–pathogen interactions is
determined by the accessibility of the lipoglycans to the
immune system, i.e. can cell wall-bound lipoglycans be
recognized by the pattern-recognition receptors (PRRs) of
the immune system and how do the lipoglycans trafﬁc, once
released from the mycobacterial cell wall?
The localization of PIMs and lipoarabinomannan in the
mycobacterial cell envelope has been assessed in multiple
ways, including biotin tagging of lipoarabinomannan and
extraction of lipids from the cell wall with detergents or by
mechanical treatment withglass beads. Because of the strong
conditions needed to extract lipoarabinomannan from the
cell wall, and the possibility to detect lipoarabinomannan
with lipoarabinomannan-recognizing antibodies on whole
cells, it was hypothesized that lipoarabinomannan is ﬁrmly
attached via its MPI anchor to the surface of the cell
(Chatterjee & Khoo, 1998). Biotin labeling, assumed to be
restricted to the cell surface, showed two fractions of
lipoarabinomannan: one anchored to the cytosolic mem-
brane and one in the mycobacterial outer membrane
(mycomembrane) (Hoffmann et al., 2008; Pitarque et al.,
2008). However, biotin is only a small molecule and may
have easier access to lipoarabinomannan more buried in the
cell wall as compared with the large PRRs, which may reduce
the potential of lipoarabinomannan to be recognized by the
immune system. Furthermore, native mycobacterial cells are
surrounded by a capsule, which could cover lipoarabino-
mannan. The mycobacterial capsule mainly consists of
polysaccharides and proteins (Daff´ e & Etienne, 1999).
Electron microscopy (EM) with immunogold-labeled cells
using ConA and anti-arabinan antibodies, combined with
nuclear magnetic resonance studies, showed the presence of
mannose-capped arabinomannan (Man-AM; i.e. without
the lipid anchor present in Man-LAM) in the capsule
(Ortalo-Magn´ e et al., 1995). The capsule has been reported
to have only a very low lipid content, among which are small
amounts of PIMs and virtually no lipoarabinomannan
(Ortalo-Magn´ e et al., 1996a,b). A recent study used im-
munogold-EM with monoclonal antibodies against PIM6
(F183-24), and against the mannose cap (55.92.1A1) and the
arabinan domain (F30-5) of Man-AM and Man-LAM to
detect surface localization of these lipoglycans. Unperturbed
mycobacterial cells bearing an intact capsule display good
labeling with these antibodies (Sani et al., 2010), which
conﬁrms the presence of PIM6 and Man-AM in the capsule.
In contrast, mycobacteria without a surrounding capsule
due to growth under perturbing conditions (in the presence
of 0.05% Tween-80 and mechanical agitation) hardly be-
come labeled with these antibodies. As lipoarabinomannan
is localized in the cell wall and not in the capsule, this
suggests limited surface exposure of lipoarabinomannan
and related glycans buried in the mycomembrane, even if
the capsule is not covering the cell wall. However, the
amount of lipoarabinomannan or its accessibility in these
cells grown under perturbing conditions has not been
assessed further.
Although culture ﬁltrate has been reported to contain
only trace amounts of lipids (Lemassu & Daff´ e, 1994),
studies with infected macrophages (Mj) showed intracellu-
lar trafﬁcking of PIMs and lipoarabinomannan, suggesting
that these glycolipids are substantially released from myco-
bacteria. Even release into noninfected bystander cells (Xu
et al., 1994; Beatty et al., 2000; Rhoades et al., 2003) and
subsequent presentation through CD1 glycoproteins (Scha-
ible et al., 2000) has been observed. Furthermore, isolated
PIMs and lipoarabinomannan can be incorporated into the
endomembranes and plasma membranes of different cell
types, a process requiring the MPI anchor and the mannan
core (Ilangumaran et al., 1995; Shabaana et al., 2005; Welin
et al., 2008). It can be hypothesized that the lipoglycans
released are able to modulate the immune response, for
example by interfering with phagosome maturation.
Phagosome maturation arrest
At least two strategies used by M. tuberculosis to survive in
Mj have been described. One is delay of the phagosome
maturation, i.e. prevention of fusion of the phagosome with
late endosomal and lysosomal organelles, which normally
leads to killing and digestion of a pathogen in an acid
environment (Armstrong & Hart, 1971; Russell, 2001;
Nguyen & Pieters, 2005). The other strategy is based on
escape from the phagosome to the cytosol (van der Wel
et al., 2007). In the phagosome maturation arrest, a role for
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et al., 2003b; Welin et al., 2008).
The phagosome–lysosome fusion process starts after
cytosolic Ca
21 increase. The Ca
21/calmodulin-dependent
PI3-kinase hVPS34 and its modulatory subunit p150 will
then generate the membrane-trafﬁcking lipid phosphatidy-
linositol 3-phosphate (PI3P) on the phagosomal membrane
(Vergne et al., 2004a). Both PI3P and early endocytic small
GTPase Rab5 mediate in the subsequent recruitment of
membrane tethering protein early endosome autoantigen 1
(EEA1) to the phagosome (Vergne et al., 2003a) (Fig. 6).
EEA1 plays an essential role in phagosome maturation by
interacting directly with syntaxin-6, a soluble NSF attach-
ment protein receptor (SNARE) protein involved in the
delivery of cathepsins (lysosomal hydrolases) and VoH
1-
ATPase from the trans-Golgi network to the phagosome
(Simonsen et al., 1999). The normal cytosolic Ca
21 increase
upon an infection is absent during mycobacterial uptake.
This has been hypothesized to lead to a reduced activity of
the PI3-kinase hVPS34 and an altered production of PI3P in
the case of phagocytosis of mycobacteria (Malik et al., 2001;
Chua & Deretic, 2004) (Fig. 6).
This immune evasion strategy of blocking phagosome
maturation can be mimicked by Man-LAM, which is also
able to inhibit cytosolic Ca
21 increase (Fratti et al., 2003b;
Vergne et al., 2003b) (Fig. 6). In Mj infected with M. bovis
BCG or Man-LAM-coated beads, EEA1 is excluded from the
early endosome, thereby inhibiting phagosome maturation
at the stage of recruitment of late endosomal and lysosomal
constituents and, hence, preventing acidiﬁcation (Fratti
et al., 2001). The exact mechanism of [Ca
21]cyt-modulation
byMan-LAM is not known. ForM. tuberculosis to infect Mj
without the induction of a cytosolic Ca
21 increase, phago-
cytosis via the complement receptor is required (Malik et al.,
2000), but the inhibition of phagosome maturation byMan-
LAM appears to involve binding to the MMR instead (Kang
et al., 2005). Furthermore, a role for macrophage phospha-
tase SHP-1 has been suggested, which is activated by Man-
LAM and impairs Ca
21 signaling (Ono et al., 1997; Knutson
et al., 1998; Vergne et al., 2004a).
Another possibility of interference by Man-LAM in
phagosome maturation, distinct from blocking the rise in
[Ca
21]cyt, considers a rolefor the activation of p38 mitogen-
activated protein kinase (p38 MAPK). p38 MAPK activity
may indirectly maintain Rab5 in an inactive GDP-bound
form (Cavalli et al., 2001; Vergne et al., 2004a). This is
consistent with the report that the induction of p38 MAPK
reduces the recruitment of Rab5-effector protein EEA1 to
the early endosome (Fratti et al., 2003a). Moreover, the level
of p38 MAPK activation is signiﬁcantly increased upon
infection with M. bovis BCG (Fratti et al., 2003a) and Man-
LAM was hypothesized to be a triggering component
(Vergne et al., 2004a). However, recently, it has been shown
experimentally that p38 MAPKactivation is neither induced
nor inﬂuenced by isolated Man-LAM, and thus must be
linked to other mycobacterial components (Welin et al.,
2008).
Noteworthy, lipoarabinomannan is incorporated into
membrane lipid rafts, a process that is also required for the
phagosome maturation arrest (Welin et al., 2008). Lipid
rafts are highly dynamic lipid domains, enriched in choles-
terol and glycosphingolipids, and that have been associated
Fig. 6. The role of PIMs and Man-LAM in phago-
some maturation arrest by mycobacteria.
While Man-LAM prevents lysosomal fusion and
acidiﬁcation, PIMs induce fusion with early
endosomes to obtain nutrients required for
phagosomal residence of mycobacteria.
Man-LAM appears to inhibit cytosolic-Ca
21
increase and thereby blocks the successive steps
of hVPS34 kinase activity at the phagosomal
membrane, the recruitment of Rab5, EEA1 and
Syn6 to the phagosome, and the delivery of
cathepsins and VoH
1 ATPase. The activity of PIMs
in phagosome maturation is dependent on Rab5,
but the exact mechanism is not known yet.
MMR, macrophage mannose receptor; TGN,
trans-Golgi network; CaM, calmodulin; PI,
phosphatidylinositol; PI3P, phosphatidylinositol
3-phosphate; Syn, syntaxin; EEA1, early
endosome autoantigen 1.
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has been suggested that the presence of lipoarabinomannan
in the endomembrane causes drastic reorganization of the
lipid domains and thereby fusion of the lipid vesicles
(Hayakawa et al., 2007). However, PI-LAM from avirulent
M. smegmatis is also incorporated into endomembranes,
although to a lesser extent, but it cannot prevent phago-
some–lysosome fusion nor inhibit cytosolic Ca
21 increase
(Vergne et al., 2003b; Kang et al., 2005; Welin et al., 2008).
Given that the MMR only recognizes the mannose-capped
Man-LAM and not Ara-LAM or PI-LAM (Schlesinger et al.,
1994), this is further evidence that ligation of the Man-LAM
to the MMR is required for the phagosome matura-
tion block, which appears to be restricted to the more
virulent Mycobacterium spp. A role for the MMR has been
conﬁrmed recently by showing that glycopeptidolipids from
M. avium delay phagosome–lysosome fusion by interaction
with the MMR and by an MMR siRNA knockdown in
human monocyte-derived Mj, resulting in increased
phagosome–lysosome fusion upon M. avium infection
(Sweet et al., 2009).
As mammalian phosphoinositide PI3P plays an impor-
tant role in phagosome maturation, next to lipoarabino-
mannan, other mycobacterial PI-analogs, PIMs and
lipomannan, were investigated as well for their possible
interference in phagosome maturation. While for lipoman-
nan no role in phagosome maturation arrest could be
detected (Kang et al., 2005), PIMs do have an effect,
although in a way distinct from Man-LAM (Vergne et al.,
2004b). Similar to lipoarabinomannan, PIMs can be incor-
porated into lipid rafts and, moreover, the addition of PIMs
competitively inhibits lipoarabinomannan insertion (Ilan-
gumaran et al., 1995; Welin et al., 2008). Although PIMs
seem to reverse the effect of lipoarabinomannan of prevent-
ing endosomal fusions (Welin et al., 2008), however, indica-
tions exist of a different role of PIMs in the phagosome
maturation arrest. PIMs do prevent phagosome acidiﬁca-
tion, but not by reducing the recruitment of syntaxin-6
(Fratti et al., 2003b; Vergne et al., 2004b). Instead, PIMs
induce the acquisition of endosomal SNARE protein syntax-
in-4 and the transferrin receptor (Fratti et al., 2003b; Vergne
et al., 2004a,b) (Fig. 6). Transferrin and its receptor are
recycling endosomal markers involved in iron delivery
(Clemens & Horwitz, 1996; Sturgill-Koszycki et al., 1996).
While Man-LAM arrests phagosome maturation by block-
ing the recruitment of late endosomal and lysosomal
markers, PIMs appear to stimulate fusion with early endo-
somes and thereby retrieve nutrients necessary for myco-
bacteria residing in the phagosomal compartments (Kelley
& Schorey, 2003; Vergne et al., 2004b). This process is also
Rab5-dependent (Gorvel et al., 1991), in particular when
Rab5 activity is rate limiting, but whether PIMs affects Rab5
directly or indirectly is not yet known (Vergne et al., 2004b).
Interestingly, also in the effect that PIMs exert on the
phagosome maturation, the MMR seems to play a role.
While the lower-order PIMs (PIM2) are not recognized by
the MMR, the MMR has a high afﬁnity for higher-order
PIMs (PIM5 and PIM6) (Torrelles et al., 2006). This is
consistent with the report that only in Mj stimulated with
higher-order PIMs was a signiﬁcant increase in phagosome-
lysosome fusion seen upon MMR blockade (Torrelles et al.,
2006). Thus, although PIMs and Man-LAM inﬂuence the
phagosome maturation by distinct mechanisms, both may
involve recognition by the MMR. This indicates a balance
between Man-LAM preventing maturation into the phago-
lysosome on the one hand and PIMs stimulating early
endosomal fusion to retrieve nutrients on the other (Vergne
et al., 2004b).
Inhibition of phagosome maturation by pathogenic My-
cobacterium spp. may be a critical ﬁrst step for their
intracellular survival. Mycobacteria probably display several
mechanisms to prevent lysosomal transfer, of which one is
interference of Man-LAM in the phagosome maturation
process. A M. marinum mutant that only produces lipoar-
abinomannan devoid of mannose caps showed a signiﬁcant
increase in colocalization with phagolysosomes in murine
Mj as compared with its parent strain. However, the
absolute numbers remained low in this assay (7.4%, 12.0%
and 5.0% for the wild-type, mutant and complemented
strain, respectively), and importantly, no signiﬁcant differ-
ences in bacterial survival were observed (Appelmelk et al.,
2008). Other mechanisms of phagosome maturation block-
ade, independent of Man-LAM, have been reported, for
example the secretion of SapM by M. tuberculosis, a lipid
phosphatase that hydrolyzes the PI3P on the endomem-
branes (Vergne et al., 2005), and the secretion of a eukar-
yotic-like serine/threonine protein kinase G (PknG)
(Walburger et al., 2004).
Clusters of differentiation (CD)1
CD-1 glycoproteins have been identiﬁed as important anti-
gen-presenting molecules of the immune system, next to
major histocompatibility complex (MHC) class I and II
molecules. While MHC class I and II present peptide
antigens, CD1 molecules present glycolipids, thereby cover-
ing the presentation of a large variety of both self as well as
microbial antigens (Young & Moody, 2006; de Libero &
Mori, 2009). In mycobacterial infection, CD1 ensures the
presentation of the glycolipids unique to the mycobacterial
cell wall to activate CD1-restricted T cells and is thereby
involved in shaping the immune response (Porcelli et al.,
1998; Sieling et al., 1999; Barral & Brenner, 2007).
Human CD1 molecules are expressed by a variety of
antigen-presenting cells (APC) and can be divided into three
groups: CD1a, CD1b and CD1c together form group 1, and
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Murine homologs for group 1 CD1 molecules have not been
identiﬁed, but mice do express CD1d. Group 1 CD1
molecules present lipids to a clonally diverse T-cell popula-
tion in which the precursors have unique speciﬁcity for a
single antigen (Barral & Brenner, 2007). The expression of
group 1 CD1 on isolated human myeloid APC is hardly
detectable, but it is upregulated to high levels within a
couple of days after infection with M. tuberculosis or activa-
tion by mycobacterial lipids (Roura-Mir et al., 2005) (Felio
et al., 2009). This demonstrates an apparent role of antigen
presentation by the group 1 CD1 in the clonal expansion of
T cells and, hence, the adaptive immune response against
mycobacterial infection (Roura-Mir et al., 2005; Barral &
Brenner, 2007). CD1d presents lipids to CD1d-restricted
natural killers T (NKT) cells including the subset of clonally
less diverse invariant NKT cells that display a rapid innate-
like response (Barral & Brenner, 2007). In contrast to group
1 CD1, CD1d molecules are constitutively expressed and are
reported to be downregulated during mycobacterial infec-
tion, conﬁrming their association with the innate immune
response (Roura-Mir et al., 2005; Moody, 2006). CD1e is
only restricted to myeloid dendritic cells (DCs) and is not
expressed at the cell surface and thus does not present
antigens to TCRs. In this review, we focus on CD1b and
CD1d, because these CD1 molecules bind and present PIMs
and related lipoglycans. Group 2 CD1d has been reported to
only bind lower-order PIMs, PIM2 and PIM4, but not
lipomannan or Man-LAM (Fischer et al., 2004; Zajonc
et al., 2006). In contrast, group 1 CD1b binds several
mycobacterial lipid including PIM2 and Man-LAM (Sieling
et al., 1995; Prigozy et al., 1997; Ernst et al., 1998).
The structure of CD1 molecules has similarities to the
MHC class I molecules, but shows some important differ-
ences in its binding groove, which is deeper and facilitates
the binding of two acyl chains as present in the MPI anchor
of PIMs and Man-LAM (Zeng et al., 1997; Porcelli et al.,
1998; Fischer et al., 2004). While the lipid anchoring in the
hydrophobic CD1 groove is relatively nonspeciﬁc, the TCR
recognizes the hydrophilic carbohydrate head group of the
antigens with high speciﬁcity (Moody et al., 1997). As
compared with CD1b, additional interactions between the
center of the binding groove of CD1d and the polar head
group of the PIM2 are of additive importance for the
formation of a stable glycolipid complex and subsequent
T cell recognition (Zajonc et al., 2006). In the presentation
of PIM4 by CD1d, the two additional a(1 ! 6)-linked
Manp residues are probably orientated away from the
binding groove (Zajonc et al., 2006). Considering the low
abundance of PIM4 in the mycobacterial cell wall in contrast
to (diacylated) PIM2 (Gilleron et al., 2001), presentation of
PIM4 by CD1d may not be of high biological signiﬁcance.
For group 1 CD1b, mycobacterial antigens with head groups
much larger than present in PIM2 have been described,
which raises questions regarding how these large carbohy-
drates ﬁt in the narrow space between the TCR and CD1
(Young & Moody, 2006). Higher-order PIM6 needs proces-
sing into the smaller PIM2 before being able to stimulate
CD1b-restricted T cells. A role in this antigen processing has
been implicated for CD1e, because the presence of CD1e is
required for the activation of CD1b-restricted T cells by
PIM6, and not by PIM2 (de la Salle et al., 2005). As
mentioned above, CD1e does not present lipid antigens at
the cell surface, but probably aids in endosomal/lysosomal
a-mannosidase activity to produce PIM2 by binding PIM6
similar to the other antigen-presenting CD1 molecules (de
la Salle et al., 2005). Secondly, CD1e may facilitate the
loading of other CD1 molecules (de Libero & Mori, 2009).
How Man-LAM is presented in the interaction between the
TCR and the CD1b-Man-LAM complex has not yet been
resolved. Man-LAM may be partly digested similar to PIM6
(Ernst et al., 1998), which is most likely, as already PIM6
with its short carbohydrate head group requires processing.
Of note, CD1b and Man-LAM do colocalize in the cell
(Prigozy et al., 1997) and CD1b is able to bind Man-LAM
(Ernst et al., 1998). Two other options have been suggested
by Young & Moody (2006). One possibility is ﬂattening of
the glycan part of Man-LAM between the TCR and CD1, so
that only one or two carbohydrate units are positioned
directly between the TCR and CD1. Multiple TCR-docking
orientations may play a role in this as well. In the second
option, Man-LAM is not presented by CD1b, but stimulates
the process of CD1-dependent T cellactivation indirectly via
the mechanisms discussed below (Young & Moody, 2006).
CD1b is the predominant group 1 CD1 molecule present
in the late endosomes/lysosomes and MHC class II com-
partments (Prigozy et al., 1997; Ernst et al., 1998; Schaible
et al., 2000) and shares with MHC class II molecules the
requirement for acidiﬁcation in order to function (Benaroch
et al., 1995; Sugita et al., 1999). PIMs and Man-LAM have
been observed to be released in the phagosomes of infected
cells and transported into the same intracellular compart-
ments (Xu et al., 1994; Prigozy et al., 1997; Schaible et al.,
2000). The low pH in these compartments causes conforma-
tional changes in the structure of CD1b including relaxation
of certain parts of its binding groove to facilitate subsequent
antigen loading (Ernst et al., 1998; Sugita et al., 1999;
Kronenberg & Sullivan, 2008; Relloso et al., 2008; de Libero
& Mori, 2009). As described above, PIMs and Man-LAM
interfere in phagosome maturation and in particular Man-
LAM has been shown to prevent endosomal acidiﬁcation
(Fratti et al., 2001). Hence, PIMs and Man-LAM likely
impede theirown presentation by CD1b. On the other hand,
mycobacterial lipids have been shown to induce the
transcription and expression of group 1 CD1 glycoproteins
at the surface of the APC by signaling through TLR-2
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involved were reported to be PIM2 and Ara-LAM extracted
from the mycobacterial cell wall (Roura-Mir et al., 2005).
However, PIM2 and Ara-LAM are poor TLR2 ligands as
discussed in the next section (Nigou et al., 2008). Copuriﬁed
lipopeptides, which are more potent inducers of TLR2
signaling, may also have induced CD1 expression in this
assay (Nigou et al., 2008; Zahringer et al., 2008).
Mycobacteria are able to interfere with the immune
response against mycobacterial infection including the
modulation of peptide antigen presentation by MHC class I
and II molecules (Kaufmann & Schaible, 2005). Therefore,
the lipid antigen presentation via four different CD1 glyco-
proteins forms an important alternative mechanism to
induce an effective immune response (Sugita et al., 1999).
Although the function and expression of CD1 molecules can
be impaired by mycobacteria or mycobacterial components
such as capsular a-glucan (Gagliardi et al., 2007, 2009;
Balboa et al., 2010), the many distinct pathways for antigen
sampling from various intracellular localizations and their
subsequent presentation circumvents the immune evasion
strategies exploited by mycobacteria (Sugita et al., 1999;
Kaufmann & Schaible, 2005; de Libero & Mori, 2009).
Furthermore, both group 1 and group 2 CD1 presentation
of lipid antigensseem to play a potential role in the pro-
tection against tuberculosis by vaccination with BCG
(Watanabe et al., 2006; Venkataswamy et al., 2009).
TLRs
Three TLRs have been implicated to play a role in the
mycobacterial infection: TLR2, TLR4 and TLR9 (Ozinsky
et al., 2000; Quesniaux et al., 2004a; Jo, 2008). PIMs,
lipomannan and lipoarabinomannan have all been exam-
ined for signaling via TLR2 and via TLR4, of which an
overview is given here.
Lipoproteins are the major ligands for TLR2 (Brightbill
et al., 1999), but MPI-anchored mannosylated lipoglycans
can signal via TLR2 as well, depending on their degree of
acylation and mannosylation (Gilleron et al., 2006; Doz
et al., 2007; Nigou et al., 2008). TLR2 dimerizes with either
TLR1 or TLR6 in order to function (Ozinsky et al., 2000).
TLR1/TLR2 heterodimers mainly recognize triacylated lipo-
proteins, while the diacylated forms bind TLR2/TLR6
(Takeuchi et al., 2002; Akira & Takeda, 2004). Lipoglycan-
induced signaling occurs via the TLR1/TLR2 complex (Elass
et al., 2005; Gilleron et al., 2006; Nigou et al., 2008). A
positive relation exists between the length of the mannan
chain and the ability of the lipoglycan to activate TLR2
(Nigou et al., 2008). The lipoglycan bearing the largest
accessible mannan chain (i.e. not substituted with an
arabinan domain) – lipomannan – showed to be a potent
inducer of TLR2-signaling (Quesniaux et al., 2004b),
although this activity is restricted to the tri- and tetra-
acylated forms (Ac1/Ac2LM)(Gilleron etal., 2006;Doz et al.,
2007). Next to the induction of cytokines, Mj stimulated
with lipomannan displayed increased production of matrix
metalloproteinase (MMP)-9 (Elass et al., 2005). This was
due to the downregulation of the transcription of the MMP-
9 inhibitor, tissue inhibitor of metalloproteinases-1, and
dependent on TLR2. This implies a role for lipomannan in
tissue destruction by MMP-9 during mycobacterial infec-
tion via interaction with TLR2 (Elass et al., 2005). Further-
more, lipomannan induces granuloma macrophage fusion
in an in vitro granuloma model in a TLR2-dependent way
(Puissegur et al., 2007).
In the group of PIMs, both Ac1/Ac2PIM2 and Ac1/
Ac2PIM6 have been reported to signal via TLR2, irrespective
of their acylation pattern (Jones et al., 2001; Gilleron et al.,
2003). Further, in two studies, cellular activation via TLR2
by non-mannose-capped lipoarabinomannan (PI-LAM/
Ara-LAM) from rapidly growing species has been observed
(Means et al., 1999; Underhill et al., 1999), but not for M.
tuberculosis or BCG-derived Man-LAM. In addition, an
inﬂammatory response induced by PI-LAM from M. smeg-
matis in mice appeared to be TLR2 dependent (Wieland
et al., 2004). However, in a comparative study of all
lipoglycans, Ac1/Ac2PIM2, PI-LAM and Ara-LAM were
shown to be poor inducers of TLR2 signaling as compared
with lipomannan and Ac1/Ac2PIM6 (Nigou et al., 2008).
This is consistent with an earlier study showing that in
contrast to lipomannan, neither Ara-LAM from M. chelonae
nor Man-LAM and Ac1/Ac2PIM2 from Mycobacterium kan-
sasii mediate TLR2-dependent activation (Vignal et al.,
2003). Moreover, chemical degradation of the arabinan
domain of Man-LAM from M. kansasii restored its ability
to induce cytokine secretion via TLR2, which suggests that
the arabinan domain prevents the proper interaction of
Man-LAM with TLR2 (Vignal et al., 2003). This was con-
ﬁ r m e db yar e c e n ts t u d yb yB i r c het al.( 2 0 1 0 )i nw h i c h
lipoarabinomannan containing a truncated arabinan domain
from an M. smegmatis AftC knockout mutant showed
enhanced TLR2 signaling as compared with wild-type lipoar-
abinomannan. The positive effects of lipoarabinomannan in
the earlier reports could be due to contamination of the
lipoarabinomannan extract with lipopeptides (Nigou et al.,
2008; Zahringer et al., 2008; Geurtsen et al., 2009; Birch et al.,
2010). Overall, the data indicate that lipomannan, and in a
minor respect PIM6, are the only signiﬁcant TLR2 ligands
from this group of mycobacterial lipoglycans.
For TLR4, only a few mycobacterial lipoglycans have been
reported as ligands. Using nonactivated Mj, only tri- and
tetra-acylated lipomannan fromM. tuberculosis and M. bovis
BCG, respectively, show signaling via TLR4 (Gilleron et al.,
2006; Doz et al., 2007). In contrast to TLR2, which can only
signal by the recruitment of adaptor proteins, Myeloid
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interleukin 1 receptor (TIR) domain-containing adapter
protein (TIRAP), TLR4 can also signal via TIR-domain-
containing adapter-inducing interferon-b and translocating
chain-associating membrane protein (Akira & Takeda, 2004;
Jo, 2008). The secretion of proinﬂammatory cytokines, by
Mj stimulated with lipomannan, is strongly dependent on
the MyD88/TIRAP pathway (Doz et al., 2007). Most prob-
ably, cell wall-associated or soluble factors other than
lipoglycans [e.g. heat shock proteins (Bulut et al., 2005)]
stimulate TLR4 signaling in M. tuberculosis infection; while
both live and ‘heat-killed’ M. tuberculosis activate cells via
TLR2, only live M. tuberculosis induces TLR4-dependent
activation excluding a major role for the heat-stable glyco-
lipids (Means et al., 1999). In Table 2, an overview is given of
all TLR signaling observed for lipomannan using TLR1/2/4/
6 knockout cells or antibodies against speciﬁc TLRs.
A few studies report on an immunosuppressive effect of
lipomannan, Ac1LM and PIMs on lipopolysaccharide-acti-
vated Mj (Quesniaux et al., 2004b; Doz et al., 2007, 2009).
These inhibitory effects were independent of their signaling
via TLR2, which partially compensated the decrease of
proinﬂammatory cytokine secretion (Quesniaux et al.,
2004b; Doz et al., 2007). Which receptor-lipoglycan ligation
is then responsible for the immunosupression is not yet
known, but it is unlikely to be the MMR (Doz et al., 2007):
in contrast to the higher-order PIMs, the MMR recognizes
lipomannan and Ac1/Ac2PIM2 only with low afﬁnity (Tor-
relles et al., 2006), while they show similar inhibitory effects
on lipopolysaccharide-activated Mj (Doz et al., 2009).
Importantly, neither lyso-PIM (monoacylated PIM) nor PI
were inhibitory in this assay, indicating the requirement of
mannosyl moiety and a diacylated MPI anchor (Doz et al.,
2009). Of note, in all these experiments, lipopolysaccharide
was used, which is a major ligand for TLR4. PIMs might
interfere in the interaction between lipopolysaccharide and
TLR4, thereby causing its inhibitory effect, but this seems
unlikely (Doz et al., 2009). However, lipopolysaccharide is a
nonmycobacterial ligand, which makes this assay system
rather artiﬁcial for the comprehension of TLR-dependent
immunomodulation by PIMs and related lipoglycansduring
mycobacterial infection. Finally, the immunomodulatory
properties of Man-LAM on both lipopolysaccharide-acti-
vated Mj and DCs have been described as well (Geijtenbeek
et al., 2003; Pathak et al., 2005). These effects of Man-LAM
can be attributed to its binding by the MMR and DC-SIGN,
respectively, which will be discussed in the next sections.
In vivo studies using TLR knockout mice are not fully in
agreement on whether TLRs are crucial for mycobacterial
clearance and host defense (Drennan et al., 2004; Ferwerda
et al., 2005) or not (Sugawara et al., 2003a,b; Nicolle et al.,
2004; Holscher et al., 2008). Importantly, TLR signaling via
the MyD88 pathway has been shown in multiple studies to
be dispensable for the induction of an efﬁcient adaptive
immune response (Fremond et al., 2004; Nicolle et al., 2004;
Ryffel et al., 2005; Holscher et al., 2008). A critical role for
TLRs then has been hypothesized in the early recognition
and killing of mycobacteria (Quesniaux et al., 2004a; Ryffel
et al., 2005; Jo, 2008). However, this innate immune
response mainly depends on MyD88 and may also involve a
MyD88-mediated pathway different from via TLR (Feng
et al., 2003; Holscher et al., 2008), which is the type I
interleukin-1 receptor (IL-1R1)-mediated signaling (Fre-
mond et al., 2007; Reiling et al., 2008). Alternatively, TLR2
activation may have a second function as a regulator by
preventing an exaggerated inﬂammatory immune response
in a later stage of mycobacterial infection (Drennan et al.,
2004; Sutmuller et al., 2006; Jo, 2008; Harding & Boom,




Mc-LM, Mk-LM THP-1 Mj TLR21CD14 Release TNF and IL-8 Vignal et al. (2003)
Mc-LM, Mk-LM, BCG-LM BMDMj TLR2 Release TNF and NO Quesniaux et al.
(2004b)
Mc-LM, Mk-LM, BCG-LM THP-1 Mj TLR2 expression MMP-9 Elass et al. (2005)
BCG-LM THP-1, BMDMj TLR1/2 Release TNF Gilleron et al. (2006)
BCG-Ac1LM THP-1, BMDMj TLR1/2, TLR4 Release TNF
Mc-LM, Mk-LM, Ms-LM, Mtb-LM human PBMC TLR2 Mj fusion into MGC in in vitro
granuloma
Puissegur et al. (2007)
BCG-Ac1LM BMDMj TLR2, TLR4 Release TNF and NO Doz et al. (2007)
BCG-Ac2LM BMDMj TLR4 Release TNF and NO
Mtb-Ac1(2)LM BMDMj TLR4 Release TNF
Mtb-LM, BCG-LM HEK/CD14/TLR2, THP-1
Mj
TLR1/21CD14 Activation NF-kB Nigou et al. (2008)
Ms, Mycobacterium smegmatis;M k ,Mycobacterium kansasii;M c ,Mycobacterium chelonae; Mtb, Mycobacterium tuberculosis; BCG, Mycobacterium
bovis BCG; Ac1/Ac2LM, tri-/tetra-acylated LM (note: in some articles written as Ac3/Ac4LM); BMDMj, bone marrow-derived macrophages; PBMC,
peripheral blood mononuclear cells; MGC, multinucleated giant cells.
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to the control of mycobacterial infection (Baﬁca et al., 2005;
Ryffel et al., 2005; Jo et al., 2007), but may play a less
signiﬁcant role than originally assigned (Reiling et al., 2008).
DC-SIGN
In contrast to the interaction between mycobacteria and
Mj, which can be mediated by several different receptors
(e.g. complement receptors, CD14, MMR, scavenger recep-
tor) (Ernst, 1998), binding of mycobacteria to DCs is for the
largest part mediated by DC-SIGN (CD209) (Tailleux et al.,
2003). DC-SIGN is a type II transmembrane tetrameric C-
type lectin containing one carbohydrate recognition domain
per monomer. It was originally hypothesized that via inter-
action with DC-SIGN, mycobacteria modulate the immune
response and thereby escape immune surveillance (Geijten-
beek et al., 2003; van Kooyk & Geijtenbeek, 2003). However,
theexact role of DC-SIGNin tuberculosis infection has not yet
been clariﬁed and is still under debate (Neyrolles et al., 2006;
Ehlers, 2009; Tanne & Neyrolles, 2010). Studies on the relation
between the level of expression of DC-SIGN in human
populations and susceptibility to tuberculosis are contradict-
ing each other, varying from a protective effect to increased
susceptibility to tuberculosis by high DC-SIGN expression or
no correlation at all (Barreiro et al., 2006; Gomez et al., 2006;
Ben-Ali et al., 2007; Vannberg et al., 2008).
In a binding study using a DC-SIGN-expressing cell line,
the lectin showed a high preference for the Mycobacterium
spp. from the tuberculosis complex, while it bound little or
not to strains from outside the complex (Pitarque et al.,
2005). On the basis of differences in the mannose-capping
degree of lipoarabinomannan between these species and the
fact that DC-SIGN only recognizes lipoarabinomannan if it
is mannose-capped, it was expected that Man-LAM would
establish the interaction between mycobacteria and DC-
SIGN as present on DCs (Geijtenbeek et al., 2003; Maeda
et al., 2003). Furthermore, DC-SIGN has a high-afﬁnity
a(1 ! 2)-linked Manp residue, which increases with chain
length (Koppel et al., 2004). The predominant mannose cap
on Man-LAM of M. tuberculosis and M. bovis BCG consists
of a(1 ! 2)-linked dimannosides, and a(1 ! 2)-linked
trimannosides are also present (Pitarque et al., 2005).
Surprisingly, an M. bovis BCG mutant, which only produces
lipoarabinomannan without mannose cap, did not bind less
to DC-SIGN and DCs as compared with wild-type BCG
(Appelmelk et al., 2008); thus, ligands for DC-SIGN other
than Man-LAM must be present in the cell wall.
Next to Man-LAM, PIMs have been examined for their
binding to DC-SIGN as well (Torrelles et al., 2006; Driessen
et al., 2009). In particular, the higher-order PIMs (PIM5 and
PIM6), with terminal a(1 ! 2)-linked Manp residues remi-
niscent of the mannose cap of Man-LAM, were of interest.
As expected, DC-SIGN recognizes the higher-order PIMs
with high afﬁnity as compared with the lower-order PIMs
(Boonyarattanakalin et al., 2008; Driessen et al., 2009).
Besides PIMs, other potential ligands in the mycobacterial
cell wall for DC-SIGN have been identiﬁed: lipomannan,
Man-AM and mannosylated lipoproteins 19 and 45kDa
(Pitarque et al., 2005), and more recently, capsular a-glucan
(Geurtsen et al., 2009) (a list is provided in Table 3). All
these compounds have been shown to bind DC-SIGN and/
or inhibit binding of M. tuberculosis to DC-SIGN. This
suggests that binding of mycobacteria to DC-SIGN and
DCs is not mediated by one dominant ligand, but that there
is a redundancy in ligands for DC-SIGN present on the cell
surface (Pitarque et al., 2005). This was supported by the
observation that even a double knockout M. bovis BCG
strain that neither produces the mannose cap on lipoarabi-
nomannan nor higher-order PIMs did not show any reduc-
tion in binding to DC-SIGN and DCs as compared with its
parent strain (Driessen et al., 2009). Moreover, this mutant
strain did not induce an altered cytokine proﬁle in DCs
(Driessen et al., 2009). All of the reported ligands for DC-
SIGN can be found in DC-SIGN nonbinding Mycobacterium
spp. as well. Hence, other factors probably determine the
binding to DC-SIGN instead of only the presence or the
absence of one or a few ligands. The afﬁnity of DC-SIGN for
speciﬁc Mycobacterium spp. may be related to differences in
the mannosylation pattern of potential ligands, the relative
abundance of various compounds at the cell surface (in
particular, a(1 ! 2)-linked Manp-containing compounds),
cell wall structure and/or capsule composition. Finally, not
all potential ligands, when cell wall bound, may be accessible
to DC-SIGN and thus of equal importance for the binding
of mycobacteria to DC-SIGN.
Table 3. Overview of reported mycobacterial ligands for DC-SIGN
Mycobacterial ligands
for DC-SIGN Discussed in
ManLAM Geijtenbeek et al. (2003); Pitarque et al.
(2005); Appelmelk et al. (2008)
ManAM Pitarque et al. (2005)
LM Pitarque et al. (2005)
(higher-order) PIMs Torrelles et al. (2006); Boonyarattanakalin
et al. (2008); Driessen et al. (2009)
19- and 45-kDa antigen Pitarque et al. (2005)
Mannosylated proteins
w Driessen et al. (2009)
Capsular a-glucan Geurtsen et al. (2009)
Mannosylated lipoprotein (19kDa) and mannosylated glycoprotein
(45kDa).
wUnidentiﬁed proteins from Mycobacterium bovis BCG whole-cell lysates
probed SDS-PAGE/immunoblot with a DC-SIGN-Fc construct. Note:a
ConA afﬁnity capture assay identiﬁed 430 putative mannosylated
proteins in Mycobacterium tuberculosis culture ﬁltrate (Gonzalez-
Zamorano et al., 2009), which constitute potential ligands for DC-SIGN.
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the immune response by mycobacteria or their mannosy-
lated lipoglycans, several in vitro and in vivo studies have
been performed. Puriﬁed mycobacterial Man-LAM, not
Ara-LAM, inhibits both lipopolysaccharide- as well as
BCG-induced maturation of DCs by reducing the expres-
sion of MHC class II and costimulatory molecules (CD80,
CD83 and CD86) as compared with untreated lipopolysac-
charide- or BCG-activated cells (Geijtenbeek et al., 2003).
Furthermore, Man-LAM has been shown to induce the
secretion of anti-inﬂammatory IL-10 in lipopolysaccharide-
activated DCs (Geijtenbeek et al., 2003). Ligation of Man-
LAM to DC-SIGN appears to interfere with lipopolysac-
charide signaling via TLR4 by the activation of serine-
threonine kinase Raf-1, which subsequently leads to acetyla-
tion of NF-kB subunit p65. Acylation of p65 prolongs and
enhances the transcription of IL10, thereby increasing IL-10
production (Gringhuis et al., 2007). Together with a study
on mice lacking SIGN receptor (SIGNR)-1, a murine
homolog for DC-SIGN, which displayed a stronger T helper
1 response upon M. tuberculosis infection and a reduced
level of IL-10 production (Wieland et al., 2007), this led to
the initial thought that the interaction with DC-SIGN is
beneﬁcial for mycobacteria.
Recently, it has been shown that Man-LAM alters the
cytokine proﬁle in lipopolysaccharide-activated DCs by
increasing the secretion of not only IL-10, but also of
proinﬂammatory IL-12 and IL-6 (Gringhuis et al., 2009).
Binding of Man-LAM or mannose-containing pathogens
like M. tuberculosis induces the recruitment of effector
proteins to a DC-SIGN signalosome, which is required for
the activation of Raf-1, followed by enhancement of the
transcription of the genes encoding IL-12 and IL-6 in a
similar manner as for IL-10 (Gringhuis et al., 2009).
Noteworthy, lipopolysaccharide is a nonmycobacterial li-
gand and both Man-LAM (Geijtenbeek et al., 2003) as well
as intact mycobacteria (Driessen et al., 2009) do not induce
IL-10 secretion in nonactivated DCs. In the context of
mycobacterial infection, further research on interference of
DC-SIGN signaling induced by Man-LAM with signaling
via TLR2 by for example BCG-Ac1LM or the 19kDa antigen
would be of interest.
A study using mouse DCs showed a higher induction of
suppressor of cytokine signaling-1 expression by SIGNR1
stimulation as compared with signaling via TLR2 (Srivasta-
va et al., 2009). Itis important to mention that seven murine
homologs for human DC-SIGN are known. Each homolog
differs in certain properties from the human DC-SIGN,
among which are the speciﬁc mannose- and fucose-struc-
tures it recognizes, and this may alter their functions
signiﬁcantly (Powlesland et al., 2006; Tanne et al., 2009).
Strikingly, human DC-SIGN transgenic mice exhibited
decreased pathology and prolonged survival during myco-
bacterial infection (Schaefer et al., 2008). A clear protective
role has recently also been shown for the murine ortholog
SIGNR3 (Tanne et al., 2009). Resistance to M. tuberculosis
infectionwas impaired in SIGNR3-deﬁcient mice, but not in
mice lacking SIGNR1 and SIGNR5 (Tanne et al., 2009).
DC-SIGN speciﬁcally recognizes the pathogenic Myco-
bacterium spp. from the tuberculosis complex (Pitarque
et al., 2005). By expressing many ligands for DC-SIGN,
DC-SIGN is the most important uptake receptor for myco-
bacteria to infect DCs. However, concluding from these last
studies, DC-SIGN-binding appeared not to be mainly
beneﬁcial for the pathogens, and DC-SIGN may function
primarily in the protection of the host. How DC-SIGN
signaling exactly optimizes the immune response against
mycobacteria, i.e. by strengthening the proinﬂammatory
response or by preventing excessive inﬂammation, remains
to be established (Ehlers, 2009) (Fig. 7).
Mannose receptor
The MMR (CD206) is a type I transmembrane monomeric
C-type lectin with eight carbohydrate recognition domains.
In addition to the complement receptors, the MMR med-
iates for a large part in the phagocytic uptake of mycobac-
teria by Mj (Schlesinger, 1993). The MMR recognizes
virulent M. tuberculosis strains Erdman and H37Rv, but not
avirulent H37Ra, which has been suggested to be caused by
subtle structural differences in Man-LAM (Schlesinger,
1993; Schlesinger et al., 1996). Furthermore, the MMR also
shows a low afﬁnity for nontuberculosis mycobacteria M.
smegmatis, M. phlei and M. kansassi, of which the ﬁrst two
species only bear lipoarabinomannan without a mannose
cap (Astarie-Dequeker et al., 1999). Although the presence
of a mannose cap on Man-LAM is essential for the recogni-
tion of lipoarabinomannan by the MMR (Schlesinger et al.,
1994), it does not completely explain the differences in
MMR-mediated uptake by Mj between the Mycobacterium
spp. (Schlesinger et al., 1996; Astarie-Dequeker et al., 1999;
Appelmelk et al., 2008). Next to the recognition of the
mannose cap on Man-LAM, the MMR furthers binds high-
er-order PIM5 and PIM6 with a preference of the triacylated
species above the tetra-acylated ones, and glycopeptidoli-
pids, but not to lower-order PIM2, lipomannan and Ara-
LAM or PI-LAM (Schlesinger et al., 1994; Villeneuve et al.,
2005; Torrelles et al., 2006). Because of their structural
similarities, mannosylated proteins and (phosphorylated)
arabinomannans and mannan may be involved as well
(Ortalo-Magn´ e et al., 1995; Dobos et al., 1996; Maes et al.,
2007; Torrelles et al., 2008a). Man-LAM and related
lipoglycans all contribute to the MMR-mediated phagocy-
tosis of mycobacteria (Villeneuve et al., 2005; Torrelles et al.,
2008b). Overexpression of Mt-ManB in M. smegmatis
results in the overproduction of PIMs, lipomannan and
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Mj is probably due to the higher amount of higher-order
PIMs, as lipoarabinomannan from M. smegmatis does not
have a mannose cap (McCarthy et al., 2005).
A role for the MMR has been implicated in many of the
immunomodulatory effects by Man-LAM and the related
glycans described above. Next to uptake of mycobacteria by
Mj via the MMR, the MMR is also involvedin the transport
of glycolipids to uninfected bystanders cells and intracellular
trafﬁcking to the late endosomal compartments (Prigozy
et al., 1997). However, in DCs, uptake of both mycobacteria
as well as of the glycolipids is performed mainly by DC-
SIGN, leaving a minor role for the MMR (Schaible et al.,
2000; Geijtenbeek et al., 2003; Driessen et al., 2009). Binding
of Man-LAM to the MMR has been further linked to the
delay of phagosome maturation (described in more detail in
the corresponding section above) (Kang et al., 2005), the
induction of MMP-9 by M. tuberculosis and Man-LAM
similar to that observed for TLR2 activation by lipomannan
(Rivera-Marrero et al., 2002) and the expansion of regula-
tory T cells (Tregs) (Garg et al., 2008). Furthermore, DCs
from MMR knockout mice secrete more IL-12p40 upon
infection with M. tuberculosis as compared with DCs from
wild-type mice (Ehlers, 2009). Thus, the MMR seems to
have an immunosuppressive function on DCs, which was
earlier shown by cross-linking the MMR on DCs with anti-
MMR antibodies and several natural ligands (Chieppa et al.,
2003). Finally, in Mj, Man-LAM suppresses lipopolysac-
charide-induced IL-12p40 secretion via the induction of IL-
1 receptor-associated kinase (IRAK)-M expression (Pathak
et al., 2005). IRAK-M negatively regulates TLR signaling
(Kobayashi et al., 2002; Jo et al., 2007) and its induction is
probably triggered by binding of Man-LAM to the mannose
receptor (Pathak et al., 2005).
Concluding, the MMR signaling may induce an anti-
inﬂammatory response. A study by Torrelles et al. (2008b)
reported, for clinical isolates of M. tuberculosis (HN885 and
HN1554) with both truncated Man-LAM and a reduced
amount of higher-order PIMs, a signiﬁcant decrease in
association with the MMR as compared with the Erdman
strain, while uptake via the CR was not altered. Phagocytosis
via the MMR may shape the nature of the immune response,
and it was suggested that due to its immunosuppressive
activity, uptake via the MMR may lead to a latent infection
instead of active disease (Torrelles et al., 2008b). Related to
this, an M. tuberculosis pimB-mutant strain (Rv0557/mgtA),
which expresses less lipomannan and Man-LAM in its cell
wall, showed an increased rate of macrophage death upon
infection as compared with its parent strain (Torrelles et al.,
2009). This does not necessarily mean increased virulence,
but may even be advantageous for the host as the more
virulent strains have been reported to inhibit apoptosis
(Torrelles et al., 2009). Although the pimB-mutant pheno-
type could not be linked to reduced association with the
MMR, the presence of high amounts of PIMs, lipomannan
and Man-LAM results in a less inﬂammatory immune
response and indicates adaptation of the mycobacteria to
their host (Torrelles et al., 2009; Torrelles & Schlesinger,
2010) (Fig. 7).
Concluding remarks
The entire repertoire of enzymes and genes involved
in the biogenesis of lipoarabinomannan and related
Fig. 7. The role of DC-SIGN and other PRRs in
the immune response against mycobacterial in-
fection. Previously, it was hypothesized that
binding to C-type lectin DC-SIGN forms an
escape route for mycobacteria to immune sur-
veillance by interfering with signaling via other
PRRs. Currently, signaling via PRRs such as DC-
SIGN, MMR and TLR2 has been suggested to
have a dual function, with both a role in bacterial
clearance or induction of proinﬂammatory cyto-
kines, as well as in preventing an exaggerated
immune response. While their main function is
then in the protection of the host, Mycobacter-
ium tuberculosis beneﬁts from binding to or
signaling via these PRRs as well, which may
promote latent mycobacterial infection instead
of complete bacterial clearance.
FEMS Microbiol Rev 35 (2011) 1126–1157 c   2011 Federation of European Microbiological Societies
Published by Blackwell Publishing Ltd. All rights reserved
1145 Structure, function and biogenesis of lipoarabinomannanglycoconjugates has almost been identiﬁed. However, unlike
C. glutamicum, many of the genes involved in biosynthesis
of these molecules in M. tuberculosis are essential for its
survival (Sassetti et al., 2003; Kaur et al., 2009; Guerin et al.,
2010; G.S. Besra, unpublished data) like its cousin
M. smegmatis (Jackson et al., 2000; Kordulakova et al.,
2002; Guerin et al., 2009; Skovierova et al., 2009), and
therefore represent excellent drug targets. Furthermore, the
identiﬁcation of enzymatic machinery is now leading to the
biophysical analysis of the three-dimensional structures of
these enzymes and the identiﬁcation of inhibitors, which
may develop into novel drugs against tuberculosis. In
addition, very little is known about the regulation of
the biosynthesis of these glycoconjugates and their respec-
tive presentation on the mycobacterial cell wall; such
studies may lead to the identiﬁcation of few more interesting
and potential targets. To date, serine–threonine kinases
have been suggested in the regulation process of mycobac-
terial glycosyltransferases (Alderwick et al., 2006b; Molle &
Kremer, 2010). However, further studies are required to
unravel the detailed mechanism of regulation in terms of the
species, composition, heterogeneity, size and length of these
polymers.
PIMs, lipomannan and Man-LAM all display several
immunomodulatory properties by interactionwith different
receptors of the immune system. Their activity depends on
their degree of acylation and mannosylation. While lipo-
mannan is mainly associated with TLR signalling, the high-
er-order PIMs and Man-LAM are recognized by the C-type
lectins DC-SIGN and the MMR. Interestingly, alveolar Mj
constitutively express the MMR (Wileman et al., 1986), but
DC-SIGN expression is only induced in alveolar Mj in the
lungs of tuberculosis-infected patients (Tailleux et al., 2005),
which may inﬂuence the disease pattern in an important,
but yet to be determined way. Both C-type lectins show
comparable recognition speciﬁcities for the mannosylated
glycolipids, and as receptors CD14 (Pugin et al., 1994) and
pulmonary surfactant protein (SP)-A (Sidobre et al., 2000)
and SP-D (Ferguson et al., 1999, 2006) also bind Man-LAM,
the interactions of mycobacteria with all these PRRs may
enhance or dampen inﬂammatory signals and thereby
determine the nature of the immune response (Ernst, 1998;
Torrelles et al., 2008a). Anti-inﬂammatory signaling
via the interaction of the glycolipids with the host immune
system can be regarded as strategies of the mycobacteria
to escape immune surveillance (Torrelles & Schlesinger,
2010), but may also be vital in the prevention of an
exaggerated inﬂammatory response (Jo, 2008). As only
5–10% of the tuberculosis-infected persons develop the
active disease, the glycolipids may play a crucial role in host
adaptation of the mycobacteria and hence, a balanced
immune response resulting in a latent tuberculosis infection
(Fig. 7).
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